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Introduction
Dyspepsia as a health problem
Dyspepsia is defined as “episodic or persistent symptoms that include
abdominal pain or discomfort and which are referable to the upper
gastrointestinal tract”.1 Upper abdominal pain or discomfort, bloating, nausea,
vomiting, early satiety, heartburn and regurgitation are frequently experienced
dyspeptic complaints. In the Western population, roughly 30-40% of the
general population suffers at least once a year from dyspepsia.2-6 Only the “top
of the iceberg” of dyspeptic complaints is seen in both primary and secondary
care. Roughly a quarter of the patients with dyspepsia consults a physician, in
most cases a general practitioner (GP).4 The majority of dyspeptic disease is
self-limiting, 75% of the consulting patients is symptom-free after one year.7
The aetiology of dyspeptic complaints varies considerably. At endoscopy
relevant organic disease is found in 30-45% (5-15% peptic ulcer disease, and 25-
30% gastro-oesophageal reflux disease, with or without oesophagitis).8 Gastro-
oesophageal malignancies are rare, with a prevalence of less than 1% in all
dyspeptic patients. 8-10 More than half of the patients are considered to have
functional dyspepsia, i.e. no organic abnormalities are found at endoscopy.
Traditionally, patients presenting in primary care with uncomplicated
dyspepsia are being managed using empirical antisecretory or prokinetic
therapy. This strategy is based on the fact that dyspeptic complaints in primary
care generally disappear spontaneously.7,11-14 Only those patients that present
themselves with alarm symptoms in relation to the dyspepsia (i.e. dysphagia,
persistent vomiting, haematemesis, epigastric mass, unintentional weight loss
and iron deficiency anaemia) will be referred for endoscopy immediately.
About 7% of all consultations in primary care in the Netherlands regard
dyspeptic complaints.15 Of these consulting patients 15-20% is being referred
for further investigation, including endoscopy.16,17 This means that for the
majority the exact cause of the dyspepsia remains unknown; referred to as
“uninvestigated dyspepsia”.
The severity and frequency of symptoms is only weakly associated with the
likelihood of consultation, but concerns about malignancy and heart disease
have a great impact on consultation behaviour.18 Despite its relatively good
prognosis, dyspepsia is known to have an impact on general health, daily
activities and social activities.7,19 Dyspepsia also has a great impact from an
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economic point of view. In the Netherlands proton pump inhibitors (PPIs) and
H2-receptor antagonists (H2RAs) account for 10% of the annual
pharmacotherapy budget. Within the last 4 years costs for dyspeptic
medication have increased by 60%, mainly due to a rise in PPI prescription.20,21
Similar increases in prescription rates have been described in other countries.22
Role of Helicobacter pylori in dyspeptic complaints
The discovery of the bacterium Helicobacter pylori (formerly known as
Campylobacter pyloridis) by Warren and Marshall which was published in 1984
opened a new era for the treatment of peptic ulcer disease (PUD).23 H pylori
infection is accepted as the most common cause of gastritis, and is
aetiologically involved in gastric ulcer, duodenal ulcer and primary gastric B-
cell lymphoma.24-27 Eradication of the infection prevents PUD relapses. 28-32 The
role of H pylori infection in patients with reflux-disease and functional
dyspepsia however, is not clear-cut.
H pylori causes chronic gastritis in the stomach, via atrophic gastritis
metaplasia in the stomach may develop. Several studies have shown that in
patients on long term PPI treatment the development of atrophic gastritis is
accelerated in the presence of H pylori infection. This supports the
recommendation that eradication of the bacteria should be performed in these
Table 1 Indications for H pylori testing and treatment
Accepted indications
• Documented gastric or duodenal ulcer
• History of peptic ulcer disease
• Gastric mucosa associated lymphoid tissue lymphoma (MALT)
• Gastrectomy for ulcers or cancers
Controversial indications
• Non-ulcer dyspepsia
• Patients on NSAID treatment
• Patients on long term treatment with a PPI
• Patients with a family history of gastric cancer
• Patients with severe gastritis
• Gastro-oesophageal reflux disease
Not currently indicated
• Asymptomatic patients
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patients in a possible attempt to prevent transition to gastric cancer.26,33-35
However, others suggest that eradication of H pylori in patients leads to an
increase of reflux-disease, probably through pre-existent oesophageal sphincter
dysfunction and susceptibility to reflux disease.36-38 In other studies this could
not be confirmed.39-41
There is no clear relationship between H pylori infection and non-ulcer
dyspepsia (NUD). Some meta-analysis suggest a minor benefit of H pylori
eradication therapy in NUD, while others contradict this.42,43 These conflicting
results do not warrant recommendations for H pylori treatment in primary care
NUD patients.44-49
H pylori tests, invasive and non-invasive
For the detection of infection with H pylori, many tests and test-methods are
available (table 2). In patients that are referred for endoscopy invasive methods
for H pylori determination can be used. However, as this is an expensive
diagnostic procedure, not favoured by many patients, non-invasive tests are
more attractive for dyspepsia management in primary care. These tests are
cheap, easily accessible and test results are known within a short time span so
that the GP can immediately initiate the necessary treatment. The
characteristics of non-invasive H pylori tests have been evaluated both in the
primary and secondary care setting.9,50-56 Prevalence and severity of disease
have a strong impact on the performance of tests.57 Therefore, tests with a good
performance in secondary care do not necessarily perform as well in primary
care, as the variety of disease (and therefore the pre-test probability of that
particular disease) differs strongly. In addition, the circumstances under which
the tests are performed (laboratory, trained staff, logistics) have a strong
impact on the test performance. Many of the test validations for non-invasive H
pylori tests were performed without a reference standard (gold standard), and
only few compared different non-invasive tests within the same study
population. So far, the 13C urea breath test, which is known to have the best test
characteristics of the available non-invasive tests, has not been validated in
primary care.
Research question 1
What is the best non-invasive test for H pylori diagnosis in primary care?
14                                                                                                                        Chapter 1
At present, the ELISA seems most attractive for primary care H pylori
diagnostics. It has acceptable test capabilities, is low priced and widely
available for GPs. However, there is a development that may limit its future
application. The positive predictive value (PPV) of the ELISA, i.e. the
percentage of patients correctly tested positive is decreasing rapidly with the
decreasing H pylori infection rate, reaching a level that it might not be suitable
for use in primary care.58
As currently the ELISA test for detecting H pylori infection is the most widely
available non-invasive H pylori test in the Netherlands, and a new test, the
Pyloriset® EIA-G III had recently been launched, we investigated how this test
performs in primary care.
Research question 2
What is the diagnostic performance of a new immunoassay for the
detection of H pylori infection in primary care?
Table 2 Available endoscopic and non-endoscopic H pylori tests
Non-endoscopic (non-invasive) H pylori tests
• Antibody tests
- Quantitative (ELISA)
- Qualitative (serum or whole blood)
• Active tests
- Urease tests
  13C/14C-urea breath tests
  13C blood tests
- Faecal antigen tests
Endoscopic (invasive) H pylori tests
• Rapid urease tests
• Histology
• Culture
• Polymerase Chain Reaction (PCR)
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Dyspepsia management strategies
Several management approaches to dyspeptic patients in primary care have
been propagated. Some strategies focus on the symptoms with which patients
present using these as a clue to symptomatic treatment and pre-selection for
endoscopy. Others take into account the possibility of H pylori infection as the
reason for dyspeptic complaints.
Symptom based strategies
Preselection of patients at increased risk for gastro-intestinal abnormalities by
the GP based on signs and symptoms have been extensively studied.59-68 The
results of these symptom based diagnostic algorithms were often
disappointing, which might partly be explained by methodological limitations
of the studies. However, in primary care, symptom based strategies are
attractive and often proven to be as efficient as other approaches.69
Prompt endoscopy
Referral of all patients presenting with dyspepsia for prompt endoscopical
evaluation has the advantage that all patients are fully investigated.69-74
Though some studies showed the effectiveness of this approach, it is not cost-
effective in most countries.75,76
H pylori based strategies
In H pylori based strategies patients presenting with dyspepsia are being tested
for H pylori infection  before any further treatment decision.73,77-80 In case of the
test-and-treat strategy an individual tested positive will be treated with an
eradication treatment for H pylori infection and endoscopy will only be
performed in patients with persistent or recurring symptoms.
Background of this strategy is that in this way PUD and H pylori related
gastritis are effectively treated, even though the majority will not suffer from
these conditions. Its effectiveness heavily depends on the presumed advantage
of H pylori treatment in NUD. As gastric malignancies in most countries in
Europe are rare in the young age group, the strategy is only advocated in
patients under the age of 45. Some ulcer is cured, a rare cancer is prevented,
and occasionally symptoms are alleviated. In two large studies a test-and-treat
strategy in patients younger than 45 proved to be as effective as endoscopy-
based management of patients with dyspepsia.73,81 However, it should be noted
that the effectiveness for a test-and-treat strategy critically depends on the H
pylori infection rate and on the prevalence of peptic ulcer.82,83 It increases
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strongly with the a priori probability of peptic ulcer. As PUD prevalence in the
dyspeptic population is decreasing over time and H pylori infection rates are
lower, the cost effectiveness of the test-and-treat strategy will diminish
significantly. Evidence suggests that eradication will only lead to improvement
of dyspeptic complaints in a minority of patients with non-ulcer dyspepsia.
Therefore, the overall impact of a test-and-treat strategy on symptom reduction
in a population with a high prevalence of NUD will be low. The potential of a
test-and-treat strategy also depends on the ability of non-invasive H pylori tests
to detect the infection. Test characteristics of non-invasive H pylori tests vary
strongly and critically depend on the infection rate in the population studied.57
It is essential that tests have a documented accuracy in the clinical population
in which they will be used.
In case of a test-and-endoscope strategy either the H pylori infected individuals
receive an eradication therapy, and the non-infected patients will undergo
endoscopy or the non-infected patients receive empirical treatment for their
dyspepsia and the H pylori infected individuals will undergo an endoscopy.84
Aim of especially the latter strategy is to reduce the number of patients that
actually will undergo  endoscopy. Most studies on this topic regarded H pylori
testing in patients already selected for endoscopy, either deliberately or due to
inclusion bias (patient selection because of possible endoscopy in trial
participation). Therefore, results cannot be generalised to new dyspeptic
patients presenting in primary care.
Of all management strategies reviewed, none has proven to be superior in
dyspepsia management in primary care. A combination of pre-selection of
patients at risk for an organic disease with subsequent diagnostic testing has
not been studied so far. We designed a diagnostic method combining optimal
history taking with additional H pylori testing in patients suspected of peptic
ulcer disease in primary care.
Table 3 Factors determining effectiveness of a test-and-treat strategy
• Accuracy of non-invasive H pylori test in the population
• Population prevalence of H pylori infection
• Prevalence of ulcer, cancer, NUD and gastro-oesophageal reflux disease
• Cost of endoscopy, tests and treatment
• Likelihood of eliminating symptoms
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H pylori in dyspepsia management in daily practice
Surprisingly, in contrast to the large number of available H pylori related
guidelines, the impact of H pylori diagnosis on dyspepsia management in
routine practice has hardly been studied.85-87 Confusion seems to exist among
GPs, on issues such as, which patients to test, the optimal diagnostic follow-up,
and which indications to set for treatment of H pylori infections. We
investigated the current dyspepsia management and the role of H pylori in
primary care in a study among Dutch GPs. A 5% random sample of GPs filled
out a questionnaire on their dyspepsia management and H pylori testing and
treating.
Implementation research
There is a growing tendency to base clinical care on evidence based medicine.
Clinical research develops rapidly and relevant research findings have to be
introduced to health care professionals, so that they can be applied in daily
practice. However, there are conflicts between evidence-based guidelines and
daily practice. The scientific validity and reliability of guidelines receive a lot of
attention, but the features of guidelines that determine their use in clinical
daily practice remain largely unknown. Grol et al. found that in the
Netherlands in roughly 60% of the clinical decisions in primary care
recommendations from primary care guidelines are being followed.88 A good
understanding of which attributes of guidelines influence their use in daily
practice is crucial for guideline development.89  Many different approaches to
guideline implementation exist and they can be divided into the following
subgroups:90
Research question 3
What is the additional value of H pylori testing to history taking in
diagnosing peptic ulcer disease in primary care?
Research question 4
To what extent is H pylori diagnosis and treatment incorporated in
dyspepsia management in primary care in the Netherlands?
18                                                                                                                        Chapter 1
• Educational approaches: implementation via problem-based learning.
• Epidemiological approaches: in this strategy scientific literature is
summarised and the evidence behind the guidelines is stressed for optimal
implementation.
• Marketing approaches: this strategy focuses on the development and
marketing of the guideline.
• Behavioural approaches: conditioning and controlling are central themes in
this strategy. Reviewing performance and providing feedback have a
positive effect on the actual use of the guideline.
• Social interaction: this strategy is based on the idea that learning and
changing are achieved through interaction with key persons (opinion
leaders).
• Organisational approaches: this approach creates the necessary conditions
for change. Organisational and structural factors hindering change can be
eliminated.
• Coercive approaches: these focus on pressure and control as a method for
change.
The effectiveness of many of these interventions has been studied. Though
implementation strategies should, where possible, be evaluated using
randomised trials, most studies were non-experimental (i.e. observational)
studies. Most of the reviews identified modest improvement in performance
after interventions.91 So far, individual instruction, feedback and reminders
seem to be the most effective single strategies.
In the United Kingdom the effect of implementation of a new dyspepsia
guideline in primary care was studied.92,93 This study, however, addressed the
follow-up of the implementation and gave no recommendations how to
improve the adherence to the guideline. Many reviews suggest that
combinations of interventions are more effective than single ones.94  The most
effective combined strategies appear to be combinations with individual
instruction of the GPs and the combination of peer review. Remarkably,
financial incentives to stimulate implementation of a guideline have hardly
ever been evaluated.95,96
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We compared adherence to a new guideline on dyspepsia in a GP group
stimulated by financial incentive, a group receiving education and a control
group not receiving a specific intervention.
Research question 5
Does introduction of a new dyspepsia guideline in primary care by an
educational approach or by a financial incentive improve adherence to
the guideline?
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A reader’s companion to this thesis
Chapter 2
In this chapter the results are reported from a questionnaire sent to a 5%
sample of Dutch GPs, regarding their approach to Helicobacter pylori (H pylori)
diagnosis and treatment. The study was performed as a “field study” and was
used as a basis for several other studies described in this thesis.
Chapter 3
A study was performed to develop a clinical decision rule for primary care to
estimate the probability that a patient with dyspepsia has peptic ulcer disease
(PUD). The aim of the study was to be able to distinguish between patients at
high and low risk of having PUD disease and to evaluate whether H pylori tes-
ting had an additional value to optimal history taking in the detection of PUD.
Chapter 4
Many invasive and non-invasive H pylori tests exist. The test characteristics
strongly depend on the population that the test is used in. As in primary care
most patients are treated without referral, non-invasive H pylori testing is
attractive. We studied which of the (at the time of the start of the study)
available non-invasive H pylori tests was most suitable for use in primary care.
Chapter 5
The enzyme linked immunoassay (EIA) is the most widely available and used
non-invasive test for H pylori diagnosis in primary care in the Netherlands. A
newly developed serological assay, the Pyloriset® EIA-G III, was evaluated in
the primary care setting and test characteristics and optimal cut-off point were
determined.
Chapter 6
We describe a study in which a new guideline on dyspepsia was introduced in
primary care in the Netherlands. Six groups of GPs participated in the study
and were divided into three groups of GPs. Two groups of GPs received a
specific intervention for the introduction of the new dyspepsia guideline, the
third group received a minimal intervention consisting of written instruction
on the new guideline. Adherence to the guideline in the three groups and
secondary outcomes with respect to quality of life and dyspepsia of the patient,
and costs (medication prescribed, referrals, diagnostic tests etc.) were
compared in the three groups.
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Abstract
Background: Many guidelines on the management of Helicobacter pylori (HP)
related dyspepsia have been produced over the past decade. The suggested
policies in these guidelines are often more consensus- than evidence-based
(test-and-treat, test-and-endoscope), which may cause confusion among
primary care physicians.
Aim: To determine the current management of HP-related dyspepsia by Dutch
general practitioners (GPs).
Methods: A random sample of 5% of all Dutch GPs (n=355) were sent a
questionnaire on the diagnosis and treatment of HP infections in dyspepsia
management.
Results: The response rate was 66.2% (n=235). Almost 80% of the responding
GPs stated they had conducted HP testing (via endoscopy or serology) during
the previous twelve months. In the same time period more than 94% had
actually prescribed an HP eradication therapy. A total of 70% of the GPs stated
that they used endoscopy to test for HP infection, 54% used serology (ELISA),
whole blood tests and carbon urea breath tests (CUBTs) were not used. Patients
with a history of peptic ulcer disease, those on chronic acid-suppressive drugs
and patients with recurrent ulcer-like complaints were most frequently tested
for HP infection.
Conclusions: Given the frequency of consultations for dyspepsia in primary
care in the Netherlands (150 new dyspeptic patients per average practice per
year), and the reported average number of HP tests performed (1-5 per GP per
year), HP diagnosis plays a modest role in the management of dyspepsia in
Dutch general practice. Neither the test-and-treat policy recommended in the
Maastricht guidelines, nor its advice regarding the choice of diagnostic test
(carbon urea breath test or serology), is being followed. The majority of GPs
uses endoscopy for the detection of HP infection.
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Introduction
Since its discovery in 1982, much research has been conducted on Helicobacter
pylori in order to elucidate its exact role in dyspepsia. The relationship between
peptic ulcers (both gastric and duodenal) and H pylori (HP) infection has been
firmly established, while the exact relationship between HP infection and non-
ulcer dyspepsia (NUD) has not yet been clarified. A wide range of different
national and international guidelines exists on how and when to diagnose and
treat HP infections and different strategies have been proposed.1-6 The
Maastricht consensus report for example, recommends the testing and treating
of HP infection based on age and symptoms, while other reports on dyspepsia
management suggest testing and treating HP infection based on endoscopy. 3,7,8
Most guidelines for primary care restrict HP testing to patients with recurrent
dyspepsia and focus on dyspepsia related to peptic ulcer disease.5,9,10
Reports from general practice indicate that knowledge of HP, and its
involvement in dyspepsia varies widely among primary care physicians. 11,12,13
HP eradication in patients with peptic ulcer disease is reported to be far from
optimal and GPs use a wide spectrum of eradication therapies and regimens.
14,15,16 Obviously, follow-up of many guidelines is limited.
Studies have shown that compliance with guidelines depends on many
factors.17,18,19 Recommendations are followed best in general practice if they are
feasible, clear, and evidence-based and if they are written from a clinical
primary care perspective. In addition to that, optimal implementation of HP
guidelines may be hindered by restrictions in availability, access, or
reimbursement for tests. For example the carbon urea breath test (CUBT) and
whole blood tests are available in many hospitals, but their use in general
practice is not possible in many countries. Many guidelines on HP
management as stated above also give conflicting recommendations and are
not supported by firm clinical evidence (HP eradication in NUD, test-and-treat
strategy), which may cause confusion among primary care physicians. Finally,
many guidelines written by gastroenterology specialists lack the primary care
perspective of dyspepsia management: empirical treatment, selection for
endoscopy, and management based more on prognosis than on diagnosis.
Studies have shown that patient populations and disease prevalences differ in
primary and secondary care, as do diagnostic and therapeutic management
strategies for dyspepsia. This has been incorporated in the dyspepsia
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guidelines of the Dutch College of General Practitioners.10 These guidelines,
which are co-authorized by the Dutch Gastroenterology Society, advocate a
step-up empirical treatment with endoscopy in case of treatment failure and
recommend HP testing only in cases of confirmed peptic ulcer disease.
We were interested to see to what extent HP detection has been integrated in
dyspepsia management in general practice in the Netherlands ten years after
its introduction in Dutch healthcare, and whether this integration is in line with
existing guidelines. To do this, we sent a structured questionnaire regarding
management issues, diagnosis, and treatment of HP infection to a
representative sample of GPs. We present the results of this study and discuss
problems that physicians encounter in daily practice.
Methods
In June 1999, a written questionnaire was sent to a 5% random sample (n=355)
of Dutch GPs, provided by the NIVEL (World Health Organisation
Collaborating Centre for Primary Health Care in the Netherlands). A reminder
was sent to non-responders in August 1999. The questionnaire reflected the
complete spectrum of HP management in dyspepsia in primary care and
consisted of five sections. The first section analyzed access to HP tests and their
use in dyspepsia management, the second evaluated indications for testing, the
third section examined the methods of testing, the fourth reviewed indications
for treatment, and the fifth section analyzed the treatment regimens used by
the GPs. We used case scenarios to translate general terms of management to
clinical situations and to see whether answers to hypothetical questions were
put into practice consistently (see Appendix). Data entry and univariate
analysis were performed with the use of commercially available statistical
package SPSS for Windows (version 9.0). Univariate analysis included t-tests
for continuous variables and chi-square tests for categorical variables to assess
statistically significant differences between responders and non-responders.
Results
The response rate was 66.2% (n=235) after two mailings. No differences in
demographic background were found between the groups of responders and
non-responders (table 1).
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Table 1 Demographic characteristics of responders and non-responders
Responders (n=235) Non-responders (n=120)
Male 198 (84%) 93 (78%)
Female 37 (16%) 27 (22%)
Solo practice 101 (43%) 66 (55%)
Group practice 134 (57%) 54 (45%)
Urbanised area 144 (61%) 64 (53%)
Rural area 91 (39%) 56 (47%)
Dispensing GP 25 (11%) 22 (18%)
Nondispensing GP 210 (89%) 98 (82%)
Age groups
30-39 40 (17%) 19 (16%)
40-49 122 (52%) 61 (51%)
50+ 73 (31%) 40 (33%)
Frequency of testing and access to HP tests (table 2)
Almost 80% of the responding GPs stated that they had conducted HP testing
during the previous year. Of these, 55% had tested between one and five, the
other 45% had tested more than five individuals. Ninety-four percent of the
GPs confirmed having written one or more prescriptions for HP eradication
therapy during the past 12 months. Endoscopy is widely available in the
Netherlands and nearly all GPs stated having open access to it and thus to
invasive HP testing. Fifty-nine percent of the GPs noted that they had access to
an ELISA for HP diagnosis. According to the questionnaire an ELISA is the
most widely available non-invasive HP test in the Netherlands. Only 9% of the
GPs reported having access to CUBT. Testing via whole blood tests seemed
even less feasible, as only 7% of the GPs reported having access to a whole
blood test that is reimbursed.
Previous studies have shown that GPs co-operate with gastroenterologists,
microbiologists, and pharmacists in regional networks and that many of these
networks have developed their own guidelines for clinical disease
32                                                                                                                        Chapter 2
management. To study this, we enquired to what extent primary and
secondary care interfaces existed for guidelines on dyspepsia and HP
management. Thirty-six percent of the GPs stated that they had regional
guidelines for testing HP infection, while 47% reported having
recommendations on treating HP infection. According to the responses on the
questionnaire, most of the regional guidelines only discuss the treatment of HP
infected individuals (52%).
Indications for testing (table 3)
Age as such only plays a minor role in the decision to test for HP infection. In
contrast, the type of complaint plays a big role in the decision: 98% of the GPs
stated that they would request HP diagnosis in patients with ulcer-like
complaints. Roughly 30% would test patients with reflux complaints, and 27%
would test patients presenting with non-specific symptoms.
Table 2 Frequency of HP testing and access to tests
Test frequency on yearly basis (n=221)
 n   %
0 47 21.2
1-5 98 44.4
>5 76 34.4
Eradication prescription frequency on yearly basis (n=221)
 n   %
0 13 5.9
1-5 151 68.3
>5 57 25.8
Number of GPs (n=235) that have access to H pylori tests
n %
Endoscopy 214 91.1
Urea breath test 20 8.5
ELISA (serology) 138 58.7
Whole blood test 17 7.2
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The frequency and type of dyspeptic complaints strongly influenced the
approach of GPs towards HP testing. For example no HP testing was
conducted in patients presenting with a first episode of dyspepsia, while 84%
of the newly presenting patients with a history of peptic ulcer disease (both
gastric and duodenal) were tested. In contrast, patients with a history of
oesophagitis and functional dyspepsia were tested for HP infection by only
33% and 19% of the responding GPs respectively. 56% of the GPs stated that
they tested patients taking chronic acid-suppressive drugs for HP infection. A
minority of the GPs (14%) tested the partners and relatives of HP-infected
individuals regardless of the medication used, while relatives of patients with a
gastric carcinoma were tested by 18% of the GPs. Testing at the patient’s own
request was rarely done (7%).
Methods of testing (table 3)
The majority of the GPs (70%) used invasive test methods at endoscopy to
detect HP infection (via rapid urease test, culture or histology). In contrast, 54%
reported using serology (ELISA) and only 4% used CUBT and whole blood
tests.
Indications for treatment (table 4)
Only 34% of the GPs stated that they treated all patients with a proven HP
infection, regardless of symptoms, diagnosis or history. Regarding the
subgroups of HP infected individuals, 70.8% of the GPs stated that they treated
individuals that actually had dyspeptic complaints. 75.9% of the GPs indicated
that they treated infected individuals with an active peptic ulcer, 65% of the
GPs indicated they would treat infected individuals with a history of peptic
ulcer. 62.8% of the GPs stated they would treat HP infected patients on chronic
acid suppressive therapy with eradication therapy.
Treatment regimens (table 4)
Triple therapy consisting of a combination of one proton-pump inhibitor and
two types of antibiotics was prescribed most frequently for proven HP
infection (85%). A smaller group of GPs (13%) used quadruple therapy
consisting of triple therapy as stated above and bismuth subcitrate. Only a
minority used a combination of bismuth subcitrate and two types of
antibiotics. A total of 86% of the GPs prescribed eradication therapy for one
week, while the other 14% treated for two weeks. When the therapy failed
(symptoms of dyspepsia persisted or recurred), 10% of the GPs prolonged the
antibiotic treatment, while 62% consulted a gastroenterologist or
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Table 3 Indications for testing
Does age play a role in the decision to test for HP infection? (n=132)
Yes 42 (31.8%)
No 90 (68.2%)
Does type of complaint play a role in the decision to test for HP infection?
(n=138)
No  28 (20.3%)
Yes 110 (79.7%) Namely (n=105):
Ulcer-like complaints 103 (98.1%)
Reflux-like complaints 28 (26.7%)
Functional dyspepsia 32 (30.4%)
Does the frequency of complaints play a role in the decision to test for HP
infection? (n=137)
Yes 123 (89.8%)
No 14 (10.2%) Testing at first episode of dyspepsia (n=114)
Yes 1 (<1%)
No 113 (99%)
Which, if any, patients with a medical history of dyspepsia are tested for HP
infection? (n=137)
Past peptic ulcer 115 (83.9%)
Past oesophagitis 45 (32.8%)
Functional dyspepsia 26 (19%)
Which, if any, special groups are tested for HP infection? (n=137)
Patients at their own request 10 (7.3%)
Partners/family of HP infected individuals 19 (13.9%)
Patients on maintenance therapy with PPIs/H2RA 77 (56.2%)
Relatives of patients with gastric carcinoma 24 (17.5%)
Which tests are used for diagnosis of HP infection? (n=138)
Invasive HP test at endoscopy 97 (70.3%)
Serology (ELISA) 75 (54.3%)
Urea breath test 6 (4.3%)
Whole blood test 6 (4.3%)
(PPI: proton-pump inhibitor, H2RA: H2-receptor antagonists)
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Table 4 Indications and regimens for treatment
Indication for eradication therapy (n=137) Number      (%)
Patients that have dyspeptic complaints 97 (70.8 %)
Patients with a peptic ulcer in the past 89 (65%)
Patients with an active peptic ulcer 104 (75.9%)
Patients on chronic acid suppressive drugs 86 (62.8%)
Composition of eradication therapy (n=143)
Triple therapy: PPI and two types of antibiotics 122 (85.3%)
Triple therapy:
bismuth subcitrate and two types of antibiotics 3 (2.1%)
Triple therapy:
ranitidine bismuth subcitrate and two types of antibiotics 0
Quadruple therapy:
PPI, bismuth subcitrate and two types of antibiotics 18 (12.6%)
Length of treatment (n=138)
One week 119 (86.2%)
Two weeks 19 (13.8%)
In case of therapy failure (n=135)
Prolong the treatment 13 (9.6%)
Consult a specialist 83 (61.5%)
Change the combination of medication 39 (28.9%)
Follow up the treatment (n=138)
No 56 (40.6%)
Yes 22 (15.9%)
In case of symptoms only 60 (43.5%)
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microbiologist for treatment advice. The GPs who did not prolong treatment or
consult a specialist either tested for bacterial resistance, changed from triple to
quadruple therapy, repeated the endoscopy, or allowed some extra time for
improvement of the patient’s complaints. Regarding follow-up after
eradication treatment, only 16% of the GPs stated that they monitored every
patient for successful eradication. The largest group of GPs (43%) stated that
they only retested for infection if symptoms of dyspepsia persisted or recurred.
Of those GPs who confirmed HP eradication, 65% used endoscopy, while 25%
used serology and 10% the CUBT and whole blood test. This control was
usually performed three months after eradication therapy completion.
Discussion
Given the frequency of consultations for dyspepsia in primary care in the
Netherlands (150 new dyspeptic patients per average practice per year), and
the reported average number of HP tests performed (1-5 per GP per year), this
survey shows that HP testing plays a very modest role in the management of
dyspepsia in Dutch general practice.20 The main indication for HP testing in
Dutch primary care is recurrent dyspepsia, especially in patients with a history
of peptic ulcer and ulcer-like complaints. In the majority of cases the testing is
done via an invasive method. In case of proven infection triple therapy is used
most often. Confirmation of eradication treatment is only conducted in patients
with persistent symptoms.
There are a few possible limitations to this survey. Selection bias which
influences the groups of responders and non-responders, for example, cannot
be ruled out. Nevertheless, we think that the results can be generalized to daily
practice as no differences existed between the groups of responders and non-
responders. Another limitation is the draw back of any anonymous
questionnaire: it investigated only what GPs say they do in daily practice, not
what actually happened. We tried to overcome this problem by including case
scenarios.
In the Netherlands, GPs see 150 new dyspeptic patients annually, and have
between 50 and 100 patients on maintenance therapy with proton-pump
inhibitors and H2-receptor antagonists per practice. Given the results of this
survey, less than 10% of the patients diagnosed for the first time with
dyspepsia are tested for HP infection. Surprisingly high, however, is the
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number of different regional guidelines on HP management at the
primary/secondary care level. It would be worthwhile to look at the contents
of these guidelines.
Although the predictive value of symptoms is disputed, our survey shows that
test indications are mainly directed by symptomatology. The fact that mainly
patients with recurrent dyspepsia are being tested might be a reflection of the
fact that most dyspeptic patients in primary care have a good prognosis and
often only consult their GPs once. The Dutch guidelines on dyspepsia
recommend the use of empirical treatment consisting of acid-suppressive
drugs before further investigation of the dyspepsia is conducted. According to
our questionnaire nearly all Dutch GPs follow this recommendation.
The reported use of test methods is a reflection of the availability of HP tests in
the Netherlands. Most GPs prefer HP testing during endoscopy. The low use of
other methods might be explained by the local situations. For example, the
CUBT is only available in certain university medical centres and is usually only
reimbursed if it is performed at the request of a specialist. Whole blood tests
are not reimbursed for primary care use and therefore cannot be used in a GP’s
office as a quick diagnostic tool. In addition, studies have shown that the
performance of whole blood tests in daily practice is disappointing.21 Although
an ELISA is reimbursed in full, it is only used by approximately half the GPs
probably partially due to unfamiliarity with its merits.
It is also quite surprising that the GPs’ answers indicate that not all HP infected
patients - though tested and found positive - are actually treated. The question
arises: why are so many patients being tested if the results do not have further
consequences for treatment? To improve this situation, either less HP testing
should be done or more treatment should be given to HP-infected individuals.
According to the questionnaire, treatment regimens in the Netherlands do not
vary much. Moreover, many GPs reported having guidelines on eradication
strategies for HP infections and that they are being followed. This is probably
the reason for the low resistance rate to antibiotic treatment in the Netherlands.
22
On some aspects, HP management in Dutch primary care does not follow the
Maastricht guidelines. However, it is in line with the recommendations of the
Primary Care guidelines of the ESPCG and Dutch College of General
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Practitioners. Compliance with guidelines depends, amongst other factors, on
practicality, partnership, feasibility and evidence-based level of the
recommendation.19,23 The absence of  CUBT test facilities in the Netherlands,
and the lacking evidence for the benefit of a test-and-treat strategy may explain
why Dutch GPs do not follow the Maastricht recommendations.
The low incidence of HP treatment in patients with a history of peptic ulcer
disease is worrying. It may be explained by the hesitation that many GPs feel
to change treatment in patients who are doing well on chronic acid
suppression. More effort needs to be put in education about the benefit of HP
eradication as a cost-effective alternative to acid suppression in these patients.24
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Appendix
Case scenario 1
A male patient has epigastric pain and visits your practice. In which situation
would you test this patient for HP infection?
If he is older than 45
At a second episode of pain
If the complaints are ulcer-like   
If acid-suppressive drugs have no effect
I never test for HP infection
Case scenario 2
A patient has had an endoscopy two years ago and no abnormalities were
found. The patient returns to your practice with complaints suggestive of
functional dyspepsia. What do you do?
Prescribe prokinetic drugs
Prescribe acid-suppressive drugs
Refer for an endoscopy    
Perform a HP test
I do not prescribe anything
Case scenario 3
A male patient has had an endoscopically proven duodenal ulcer 10 years ago
and has been taking ranitidine ever since. He asks for a renewal of the
ranitidine prescription. What do you do?
Prescribe the ranitidine
Suggest testing for HP infection  
Suggest giving an eradication treatment
Case scenario 4
A patient tested H pylori positive via serology and you prescribed eradication
therapy. The dyspeptic complaints have not disappeared. What do you do?
Prescribe a different eradication therapy   
Re-test the patient for HP infection
Refer for an endoscopy
Refer the patient to a specialist

Chapter III
Helicobacter pylori testing in dyspeptic patients
suspected of peptic ulcer disease in primary care;
development of a simple diagnostic scoring rule
Catherine F Weijnen1, Mattijs E Numans1, Niek J de Wit1, André JPM Smout2,
Karel GM Moons1, Theo JM Verheij1, Arno W Hoes1
1 Julius Center for General Practice and Patient Oriented Research, UMC,
Utrecht
2  Department of Gastroenterology, UMC, Utrecht
Published as: Weijnen CF, Numans ME, de Wit NJ, Smout AJPM, Moons KGM,
Verheij TJM, Hoes AW. Testing for Helicobacter pylori in dyspeptic patients
suspected of peptic ulcer disease in primary care: cross sectional study. British
Medical Journal 2001;323:71-5. Reprinted with kind permission of the
publication holder: the BMJ group, United Kingdom.
44                                                                                                                        Chapter 3
Abstract
Objectives: To develop an easy applicable diagnostic scoring rule to determine
the presence of peptic ulcers in dyspeptic patients in the primary care setting,
and to evaluate whether Helicobacter pylori (H pylori) testing has added value to
optimal history taking.
Design: Cross-sectional study.
Setting: Patients selected from general practitioner’s offices in the area of
Utrecht, the Netherlands.
Participants: 565 primary care patients consulting the general practitioner with
dyspeptic complaints lasting at least two weeks.
Main outcome measures: The presence or absence of peptic ulcer. Independent
predictors of the presence of peptic ulcer as obtained from history taking and
the added value of H pylori testing were quantified using multivariable logistic
regression analyses.
Results: A history of peptic ulcer, pain on an empty stomach and smoking were
strong and independent diagnostic determinants of peptic ulcer disease with
odds ratios of 5.5 (95% CI 2.6-11.8), 2.8 (95% CI 1.0-4.0) and 2.0 (95% CI 1.4-6.0),
respectively. The ROC area of these determinants together was 0.71. Adding
the H pylori test increased the ROC area to only 0.75. However, in a high-risk
patient group, identified by means of a simple scoring rule based on history
taking, the predictive value for the presence of peptic ulcer increased from 16%
to 26% after a positive H pylori test.
Conclusions: In the total group of dyspeptic patients in primary care H pylori
testing has no value in addition to history taking in diagnosing peptic ulcer
disease. In a subgroup of patients at high risk for having peptic ulcer disease,
however, it might be useful to test-and-treat for H pylori infections.
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Introduction
Dyspepsia is a common problem.1 Although the vast majority of patients
presenting with dyspepsia in primary care has no organic disease, a small
minority of patients suffers from peptic ulceration and would benefit from
specific treatment, notably if the ulcer is related to Helicobacter pylori (H pylori)
infection.2 Although the number of H pylori-negative peptic ulcers is increasing
in time, the majority is still related to H pylori infection and accounts for
significant morbidity and mortality.3-4 In view of this, non-invasive test-and-
treat policies for H pylori infections have been promoted in order to improve
early ulcer detection and treatment in dyspeptic patients.5-10 In a recently
published systematic review, Moayeddi et al. stated that H pylori eradication is
also of modest benefit in patients with non-ulcer dyspepsia.11 This benefit,
however, (15 non-ulcer dyspepsia patients should receive H pylori eradication
therapy to reduce complaints in only one patient) seems too small to promote
H pylori test-and-treat strategies for all dyspeptic patients. Furthermore,
although a test-and-treat strategy or the alternative strategy of direct
endoscopy in all dyspeptic patients may be cost-effective, this cost-
effectiveness would be lower in the primary care setting, with its lower
prevalence of peptic ulcers.12 In addition, the strategy involving routine
endoscopy would lead to considerable burden to the patients.
Many dyspepsia guidelines, among which those of the Dutch College of
General Practitioners, still recommend to restrict H pylori eradication to
patients with a proven peptic ulcer.13 Thus, preselection by general
practitioners of dyspeptic patients at increased risk of having peptic ulcer
disease based on symptoms and signs remains crucial. So far the performance
of such symptom-based diagnostic algorithms predicting the presence of peptic
ulcer is rather poor, although the statistical power of most studies was
limited.14-22 Furthermore, the value of a diagnostic rule combining optimal
history taking with additional H pylori testing has not been explored.
Therefore we carried out a diagnostic study to quantify which parameters from
history taking independently contribute to determining the presence of peptic
ulcer disease in patients with dyspeptic complaints in general practice, and
whether H pylori testing provides any added diagnostic value. In addition, we
aimed at developing an easy applicable scoring rule to facilitate the diagnosis
of peptic ulcer in primary care.
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Methods
Population
Data were obtained from three different studies with similar in- and exclusion
criteria, performed at our department, all regarding primary care patients with
dyspeptic complaints that were referred to open access endoscopy facilities in
the greater Utrecht area, between June 1996 and January 2000. Patients were
eligible for the present diagnostic study if they had had dyspeptic complaints
for at least two weeks before visiting their general practitioner. Excluded were
patients who were pregnant or presented with alarm symptoms (i.e. weight
loss, anaemia, dysphagia, gastric bleeding, vomiting and previous gastric
surgery).
Diagnostic work-up
Using a standard form, the following potential diagnostic determinants were
registered by the general practitioners: age, gender, medical history, smoking
behaviour, co-morbidity, medication and current complaints and symptoms.
Subsequently, in all patients the H pylori status was determined with at least
one of the following tests: a whole blood test, BM-Test® Helicobacter pylori
(Roche diagnostics, Rotkreuz, Switzerland), an ELISA test, Pyloriset® EIA-G
(Orion diagnostics, Espoo, Finland), and a carbon 13 urea breathtest,
Pylobactell™ (BSIA/Torbett laboratories, Chatham, United Kingdom). If one of
these tests proved to be positive, an individual was considered H pylori-
infected. Finally, all patients were referred for endoscopy in one of the
participating centres to establish a definite diagnosis (reference standard). The
study was approved by the Medical Ethics Committee of the University
Medical Center, Utrecht and written informed consent was obtained from all
participating patients.
Outcome definition
The outcome of the study was the presence or absence of peptic ulcer disease.
A peptic ulcer was considered present in case of an endoscopically
demonstrated duodenal or gastric ulcer, an erosive gastritis or a duodenitis.
Data analysis
First, the (univariable) association between each potential diagnostic
determinant obtained from history taking, and the presence of peptic ulcer
disease was quantified using the odds ratio (OR) and 95% confidence interval
(95% CI). All determinants with a p-value < 0.25, were then entered together in
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a multivariable logistic regression model to evaluate which of these was
independently associated with the presence of peptic ulcer disease. From this
overall model, model reduction was performed by excluding variables with p-
values > 0.05 in order to retain a more reduced and simple diagnostic model
containing only the strongest determinants of the presence of peptic ulcer
disease. Subsequently, this reduced model was extended with the H pylori test
result to quantify its added value in predicting the presence or absence of peptic
ulcer disease. Of each of the diagnostic models, the reliability (goodness of fit)
was assessed using the Hosmer & Lemeshow test23 and the ability to
discriminate between patients with and without peptic ulcer was quantified
using the area under the Receiver Operating Characteristic curve (ROC area).24
The ROC area is a suitable parameter to summarise the discriminative power
of a diagnostic model and can range from 0.5 (no discrimination, like a coin
flip) to 1.0 (perfect discrimination). A value of greater or equal to 0.7 is
considered to be reasonable and over 0.8 as good.25 Differences in diagnostic
discriminative value between different (reduced and extended) models were
estimated by comparison of ROC areas taking into account the correlation
between the models as they were based on the same cases.26-27
Subgroup analyses
We analysed the ability to detect peptic ulcer disease for subsets of relevant
diagnostic determinants obtained from history taking. Taking into account the
independent diagnostic determinants we identified a high-risk and low-risk
patient group using the odds ratios of the history model. The (added) value of
a non-invasive H pylori test in detecting peptic ulcer disease in these subgroups
was assessed by creating two by two tables and computing the Chi-square
statistic and the posterior probability of a positive and negative H pylori test.
Results
A total of 612 patients was enrolled in the study. In 565 of these, complete data
on medical history, current complaints, and the diagnosis according to
endoscopy were available (table 1 and table 2). Of the 565 patients, 38 (6.7%)
had a peptic ulcer detected at endoscopy. Of these 38, 22 (58%) peptic ulcers
were H pylori-related according to the non-invasive H pylori test.
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Table 1 Characteristics of primary care dyspepsia patients with and without
peptic ulcer (n=565)
characteristic peptic ulcer
(n=38)
no peptic ulcer
(n=527)
p-value
age (years) 46.3 45.3 0.67
male sex 55.3% 46.3% 0.32
NSAID use 7.1% 20.1% 0.32
hiatal hernia 2.7% 9.4% 0.24
pain after meal 39.5% 49.5% 0.24
obstruction 23.7% 25.2% 0.84
history of PUD 36.8% 7.6% <0.01
smoking 52.6% 32.2% 0.013
pain on empty stomach 71.1% 45.0% 0.002
use of H2-antagonists 43.2% 36.4% 0.48
PUD= peptic ulcer disease; NSAID= non-steroidal anti-inflammatory drug
Table 2 Endoscopic diagnosis of the 565 individuals presenting with
dyspepsia to their general practitioner included in the decision rule
Endoscopic diagnosis number of individuals     (%)
malignancy of gastrointestinal tract 4 (0.8%)
gastric ulcer 5 (0.85%)
duodenal ulcer 33 (5.8%)
mucosal damage * 214 (37.9%)
other relevant disease † 5 (0.85%)
minor disease ‡ 179 (31.7%)
no abnormalities 125 (22.1%)
* Mucosal damage: oesophagitis, bulbitis, severe gastritis
† Other relevant disease: achalasia, polyps, Schatzki’s ring, oesophagus varices
‡ Minor disease: hiatal herna, gastro-oesophageal prolaps, chronic gastritis
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Table 3 Relationship between history variables and the presence of peptic
ulcer disease in 565 patients presenting with dyspepsia in primary
care. Results of univariable and multivariable analyses.
unadjusted odds
ratio (95% CI)
adjusted odds
ratio (95% CI)
adjusted odds
ratio (95% CI)
age per year 1.0 (0.9-1.1) * *
NSAID use 0.3 (0.04-2.3) * *
hiatal hernia 0.3 (0.03-1.9) * *
pain after meal 0.6 (0.3-1.2) * *
obstruction 0.9 (0.4-2.0) * *
history of PUD 6.4 (3.1-13.5) 5.5 (2.6-11.8) 4.6 (2.1-10.1)
smoking 2.2 (1.2-4.3) 2.0 (1.0-4.0) 1.9 (0.9-3.8)
pain on empty stomach 3.0 (1.5-6.2) 2.8 (1.4-6.0) 2.8 (1.3-5.9)
non-invasive Hp  test 3.1 (1.6-6.0) * 2.7 (1.4-5.5)
NSAID: non-steroidal anti-inflammatory drug; PUD: peptic ulcer disease; CI: confidence
interval
* not included in multivariable regression analysis.
History of peptic ulcer disease, smoking, pain on empty stomach and the non-
invasive H pylori test were associated with the presence or absence peptic ulcer
disease (table 3) and selected for multivariable analyses. Of these four history
variables, only smoking, pain on an empty stomach and history of peptic ulcer
disease were independent predictors of peptic ulcer disease (table 3). The ROC
area of this history model based on these three history items was 0.71 (95% CI:
0.62-0.81). Adding the non-invasive H pylori test to this model increased the
ROC area to 0.75 (95% CI: 0.66-0.83, figure 1). This increase was not statistically
significant (p=0.46). The goodness-of-fit of both models proved to be sufficient.
Although the H pylori test was independently associated with the presence or
absence of peptic ulcer disease in the total patient group, as indicated by the
odds ratios with 95% confidence interval in table 3, it did not contribute to a
better discrimination beyond history taking, as indicated by the small increase
in ROC area.
Subsequently, the value of H pylori testing in subgroups of patients with high-
or low-risk of peptic ulcer disease, based on history taking, was estimated.
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Figure 1 ROC curves deduced from multivariable logistic regression
analyses including the three diagnostic determinants (history of
peptic ulcer, smoking and pain on empty stomach) without or with
additional non-invasive H pylori testing (n=565).
AUC 1: area under the curve of the diagnostic function including the 3
diagnostic determinants from patient history: 0.71 (SE: 0.05)
AUC 2: area under the curve of the diagnostic function including the 3
diagnostic determinants and a non-invasive H pylori test: 0.75 (SE: 0.05)
Using the odds ratios in table 3 a scoring rule was developed, including history
of PUD (weight=2), smoking and pain on empty stomach (both weight=1). The
high-risk group was defined as a score of 2 or higher and the low-risk group as
<2. Accordingly, 135 high- and 430 low-risk patients were identified. The a
priori probability (prevalence) of peptic ulcer disease in the high-risk group
was 16% (22/135) and only 4% (16/430) in the low-risk group (table 4). In the
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Association between the result of non-invasive H pylori testing and
the presence of peptic ulcer disease in dyspeptic patients in
primary care (n=565). Patients were categorised as being at a high-
or low risk of peptic ulcer disease according to a scoring rule, based
on history taking.
Table 4
high-risk‡ low-risk† total
Ulcer+ Ulcer- Ulcer+ Ulcer-
H pylori+ 14 40 8 112 174
H pylori- 8 73 8 302 391
Total 22 113 16 414 565
‡ High-risk group (2 or more points according to the scoring rule) contains the following
individuals:
- history of peptic ulcer or
- smoking and pain before the meal or
- history of peptic ulcer, smoking and pain before the meal
†  Low-risk group contains all individuals not included in the high-risk group
Ulcer+: peptic ulcer
Ulcer-: no peptic ulcer
H pylori+: H pylori infection according to non-invasive Hp test
H pylori-: no H pylori infection according to non-invasive Hp test
high-risk group a positive H pylori test result increased the prior probability
from 16% to a posterior probability of 26% (14/54), i.e. the positive predictive
value. A negative test result decreased the probability to 10% (8/81), i.e. the
negative predictive value. In the low-risk group the positive and negative
predictive value were 7% and 2.5%, respectively.
Discussion
Our study indicates that H pylori testing in all patients with dyspepsia in
primary care has no value in addition to history taking in diagnosing peptic
ulcer disease. However, in a subgroup of patients at high risk of peptic ulcer
disease (based on our scoring rule including the three history variables
smoking, pain on empty stomach and history of peptic ulcer) a non-invasive H
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pylori test provides additional diagnostic information as indicated by relevant
post-test changes in the probability of the presence or absence of peptic ulcer
disease.
Applying a so called test-and-treat strategy (i.e. perform a non-invasive H
pylori  test and initiate eradication therapy in those with a positive H pylori test
and provide acid suppressive therapy to the remaining patients) in all patients
presenting with dyspepsia in primary care, would lead to prescription of
eradication therapy in as much as 31% of all patients, while in only 12.6% of
these a peptic ulcer is present. This would exhibit unnecessary costs and
potential side effects, including the development of resistance to antibiotics.
Restriction of non-invasive H pylori testing to patients preselected as high-risk
patients according to our scoring rule based on history variables, seems a more
appropriate recommendation. In these individuals the risk of having a peptic
ulcer is considerable (16.3%) and peptic ulcer treatment could be initiated
without prior gastroscopy. A H pylori test-and-treat strategy in these patients
would result in prescription of eradication therapy in only 9.6% of all
dyspeptic patients, while in 26% of these a peptic ulcer is present. In this high-
risk group the ratio of patients “correctly” (those with peptic ulcer) or
“incorrectly” (those without peptic ulcer) receiving eradication therapy is
reasonable (1:3), while the corresponding ratio in the total group of dyspeptic
patients presenting in primary care is 1:7.
Recently Moayeddi et al reported in a systematic review that an early H pylori
test-and-treat strategy might be cost-effective in non-ulcer dyspepsia and
Lassen et al. concluded from their own research that a test-and-treat strategy is
as efficient and safe as prompt endoscopy for the management of dyspeptic
patients in primary care.11-12 We believe that both research groups failed to
recognise the benefit of preselection of patients by adequate history taking
before H pylori testing is considered and that implementation of their
recommendations would provoke many unjustified eradication therapies.
Several limitations of our study need to be addressed. Our analyses were based
on data from three previous studies by our group. As a result, different H pylori
tests were used with varying test characteristics. This might have accounted for
an underestimation of H pylori infected individuals and H pylori-related peptic
ulcers.28-29 This is confirmed by the fact that the H pylori infection rate found at
endoscopy in our patients (using biopsy specimens) was higher (41%) than the
infection rate found with non-invasive tests (31%). By using more reliable non-
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invasive test methods a higher number of H pylori-related peptic ulcers would
have been detected, which would have improved the performance of our
scoring rule. The scoring rule we developed obviously awaits prospective
evaluation in other primary care populations, in particular since the
performance of the scoring rule critically depends on the prevalence of H pylori
infection and peptic ulcer disease. Currently, the rule is being tested in several
general practitioner groups in the Netherlands.
We conclude that only for patients at high risk of having peptic ulcer disease,
adding H pylori infection testing might be useful. It will avoid endoscopies in
some, and lead to a more accurate treatment of peptic ulcer disease in most
subjects.
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Abstract
Objectives: To identify the most accurate and efficient test for diagnosing
Helicobacter pylori (H pylori) infection in primary care patients.
Study design: A whole blood test, an ELISA, and carbon 13 urea breathtest
(CUBT) were evaluated in a primary care setting and validated against two
different gold standards that used gastric biopsies.
Population: Primary care patients who had dyspeptic complaints lasting at
least two weeks and were referred for endoscopy.
Outcomes measured: Positive and negative predictive values, sensitivity and
specificity were determined for all three non-invasive H pylori tests.
Results: Data from the three non-invasive H pylori tests were available for 136
primary care dyspeptic patients referred for endoscopy. They were compared
with data from the gold standards. The positive predictive value of the whole
blood test was in the range 71-75%, the ELISA 83-86%, and the CUBT 88-92%,
while the negative predictive values were in the ranges 72-77%, 96-100%, and
95-98% respectively. The sensitivity of the whole blood test was in the range
36-42%, the ELISA 93-100%, and the CUBT 92-97%, while the specificities were
in the ranges 92-93%, 90-91%, and 93-95% respectively. The positive predictive
value of the ELISA dropped significantly at lower H pylori infection rates.
Discussion: Both the ELISA and CUBT are effective in the primary care setting,
while the whole blood tests produces inferior results. ELISA might, however,
be less suitable for detecting H pylori infection in a population with low
infection rates.
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Introduction
Dyspepsia is a common problem in the general population that frequently
induces visits to the general practitioner (GP).1 Most of these dyspeptic patients
are managed by their GP, with only a minority being referred for endoscopic
diagnosis. Because of this, the ratio of different diagnoses made at endoscopy
does not necessarily reflect the causes of dyspepsia in the population at large.
One of these causes of dyspepsia is peptic ulcer disease, which has a
prevalence of 5-10% in the general practice population.2 Studies have shown
that the key factor in peptic ulcer disease (PUD) is Helicobacter pylori (H pylori),
it causes about 75% of all ulcers.3 Testing for infection with this bacterium
might, therefore, be an important contribution to the diagnosis of peptic ulcers.
A number of strategies involving H pylori testing have already been proposed
for dyspepsia management in primary care (i.e. test-and-treat and test-and-
endoscope),4-9 all of which require valid confirmation of infection. There are
also numerous tests, invasive and non-invasive, available for the diagnosis of
infection with H pylori. Since most primary care patients are managed without
endoscopy, non-invasive H pylori tests are the most attractive ones.
Many validations of non-invasive H pylori tests (whole blood tests, urea breath
tests and ELISAs) have been reported, although they usually consider just a
single test. The tests characteristics of most office tests, such as whole blood
tests, are disappointing.10,11 An ELISA is the most commonly used serological
test and it is known to be a reliable, fast and low cost technique. The carbon 13
urea breath test (CUBT) has proven to be effective in secondary care
populations, but has so far not  been validated in the primary care setting. In
fact, most H pylori test validations are performed in secondary care populations
often in specialized laboratories.12-14 Since test performance differs between
disease stages and infection rates, such tests should be validated in the target
population in which they will be used in order to prevent spectrum bias.15 In
other words, test performance may well differ between various patient groups,
e.g., in subgroups with different endoscopic diagnoses, duration of complaints,
or ethnicity. Another important point to note is that either a suboptimal or no
gold standard diagnosis was available in many of the previously published
validation studies (i.e. reference standard error).16,17 Since the quality of test
validation is highly dependant upon the use of the best available “gold
standard”, we conducted the present study to validate three non-invasive H
pylori tests in the primary care setting against two “gold standard” reference
tests conducted on endoscopic specimens. We also evaluated test
characteristics of several clinically relevant subgroups.
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Methods
Sixty GPs in the city of Utrecht, the Netherlands, selected dyspeptic patients for
this study. Patients were eligible for inclusion if they had been dyspeptic for at
least two weeks and their age was ≥18 years. Exclusion criteria were pregnancy
and serious cardiac and/or pulmonal comorbidity. Written informed consent
was obtained from each patient participating in the study. The study was
approved by the Medical Ethics Committee of the University Medical Center
Utrecht, the Netherlands. GPs registered patient characteristics on a standard
form that contained questions regarding age, gender, medical history, smoking
behaviour, comorbidity, and medication as well as the patient’s current
complaints and symptoms. Three non-invasive Helicobacter tests were
performed after inclusion: a whole blood tests for H pylori, an enzyme-linked
immunosorbent assay (ELISA) and a carbon-13 urea breath test (CUBT). The
whole blood test was performed at the GP’s office using the BM-Test®
Helicobacter pylori (Roche diagnostics, Rotkreuz, Switzerland). The ELISA
(Pyloriset® EIA-G (Orion diagnostics, Espoo, Finland)) and CUBT were
performed at the local primary care laboratory. The breath test samples were
then analyzed at the Free University Hospital Amsterdam, Clinical Chemistry
Metabolic Unit, using the Pylobactell™ kitt (BSIA/Torbett Laboratories,
Chetham, United Kingdom). The whole blood test was considered to be
positive if both the control line and test signal line were visible. The ELISA was
considered to be positive if the H pylori antigen titer value was ≥300. The CUBT
was positive if the increase of the ratio 13C/12C was ≥3.5‰. After these tests
had been performed the patient was referred for endoscopic diagnosis. The
results of the non-invasive H pylori tests were directly sent to the researchers,
so that both the endoscopists and pathologists were blinded for these results.
Four biopsy specimens were obtained during endoscopy, two from the antrum
and two from the corpus of the stomach. One biopsy specimen form each area
was subjected to a rapid urease test (CLO™ test); the others were sent to a
pathologist for histological examination. The pathologists were also blinded for
the results of the CLO™ test performed during endocopy, but they were
informed about the endoscopic diagnosis (which is routinely added to the
pathology request form by the endoscopist to provide all relevant clinical
information.) No cultures were performed as this was not routine practice in
the participating endoscopy units. Since there is as yet no consensus with
regard to a “gold standard”  for diagnosing an infection with H pylori, we
compared the outcomes of our non-invasive tests with those of two “gold
standards” to see whether the results influenced our findings.18-21 The
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definitions of the “gold standards” we used are as follows: gold standard 1: the
results of both the CLO™ test and the histological examination were the same
(i.e., both positive or both negative); gold standard 2: the individual was
considered H pylori-infected when the results of either the CLO™ test, the
histological examination, or both were positive.
In order to evaluate test performances in different dyspepsia patient groups we
compared the test characteristics of patients having dyspeptic complaints for
more than one year with those of patients having symptoms for less than one
year. Statistical analysis was performed using SPSS version 9.0 for Windows.
Results
A total of 136 patients were included in the study between April 1999 and
January 2000. Mean age was 43.4 years and half the patients were male. The
largest subgroup of patients (38%) reported suffering from dyspepsia for more
than 12 months, while 37% had had dyspepsia for only 2 weeks–3 months and
25% between 3 and 12 months. A large proportion of patients (67%) had also
had previous dyspeptic complaints. 51% of the patients stated that they
consumed more than one unit of alcohol per day and 29% smoked. Diagnosis
at endoscopy was categorized into 6 main groups (Table 1). The most prevalent
diagnosis (41.2%)  at endoscopy was oesophagitis. A peptic ulcer was observed
Table 1 Endoscopic diagnoses of 136 primary care patients consulting their
GP because of dyspeptic complaints.
Diagnosis Number  (%) H pylori infection rate (%)
according to “gold standard”
Malignancy 0 -
Gastric ulcer 2 (1.5) 0
Duodenal ulcer 6 (4.4) 100
Gastritis 2 (1.5) 0
Oesophagitis 56 (41.2) 21.4
Minor disease† 48 (35.3) 43.8
No abnormalities 22 (16.1) 36.4
† polyps, Schatzki’s ring, hiatal herna, chronic gastritis and superficial gastritis
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Table 2  Non-invasive test characteristics vs two “gold standard” reference
tests
Whole blood test (CI) ELISA test (CI) CUBT (CI)
“Gold standard 1”: CLO™ test and histology had concordant results
(n=110)
PPV 73.7 (48.8-90.9) 84.6 (69.5-94.1) 90.9 (75.7-98.1)
NPV 77.4 (66.9-85.8) 100 98.4 (91.2-100)
Sensitivity 42.4 (25.5-60.8) 100 96.8 (83.3-99.9)
Specificity 92.9 (84.1-97.6) 91 (81.5-96.6) 95.2 (86.7-99.0)
“Gold standard 2”: At least one H pylori test was performed during
endoscopy; if one or both tests were positive, the patient was considered H
pylori infected (n=136)
PPV 71.4 (47.8-88.7) 83.3 (69.8-92.5) 87.8 (73.8-95.9)
NPV 73.8 (65.3-82.3) 96 (88.8-99.2) 95.9 (88.6-99.2)
Sensitivity 35.7 (21.6-52.0) 93 (80.9-98.5) 92.3 (79.1-98.4)
Specificity 92.7 (84.7-97.3) 90 (81.2-95.6) 93.4 (85.3-97.8)
 (CI: 95% confidence interval, PPV:positive predictive value, NPV: negative predictive value)
in only a small minority (6%) and no abnormalities were noted in 16%.
According to the invasive H pylori tests (i.e., the gold standards) H pylori
infection rates in patients with these diagnoses ranged from 0 to 100%
according to the invasive H pylori tests.
The H pylori infection status in 119 of the 136 patients was determined with
both the CLO™ test and the histological examination. The infection status in
the remaining 17 patients was determined by just one. The results of the CLO™
test and the histological examination were concordant (i.e., giving the same test
result) in 110 patients, resulting in a Kappa (measurement of agreement) of
0.83.
The test characteristics of the whole blood test, the ELISA, and the CUBT were
then evaluated against the two different “gold standard”  reference tests (Table
2 and Figure 1).  The positive predictive value (PPV)  for  the  ELISA was in the
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Table 3 Test characteristics in subgroups based on duration of dyspeptic
complaints
Whole blood test (CI) ELISA test (CI) CUBT (CI)
Duration < 1 year (n=52)
PPV 54.5 (23.4-83.2) 75.0 (55.1-89.3) 82.6 (61.2-95.1)
NPV 72.7 (60.4-83.0) 96.1 (86.5-99.5) 96.0 (86.3-99.5)
Sensitivity 25.0 (9.7-46.7) 91.3 (72.0-98.9) 90.5 (69.6-98.8)
Specificity 90.6 (79.3-96.9) 87.5 (75.9-94.8) 92.3 (81.5-97.9)
Duration > 1 year (n=84)
PPV 90.0 (55.5-99.7) 94.7 (74.0-99.9) 94.1 (71.3-99.8)
NPV 77.8 (60.8-89.9) 95.8 (78.9-99.9) 95.1 (78.9-99.9)
Sensitivity 52.9 (27.8-77.0) 94.7 (74.0-99.9) 94.1 (71.3-99.8)
Specificity 96.6 (82.2-99.9) 95.8 (78.9-99.9) 95.8 (78.9-99.9)
CI: 95% confidence interval, PPV: positive predictive value, NPV: negative predictive value
range 83-86%, for the CUBT 88-92%, and for the whole blood test 71-75%; the
negative predictive values (NPV) were,  respectively,  96-100%,  95-98% and 72-
77%. The sensitivity of the ELISA was in the range 93-100%, for the CUBT 92-
97%, and for the whole blood test 36-42%; the specificities were, respectively
90-91%, 93-95%, and 92-93%. Infection rates varied between 21.4% and 36.7% in
the groups with relevant mucosal damage, relevant disease, minor disease, and
no abnormalities (Table 1).
The H pylori infection rate was higher in the group of patients with dyspeptic
complaints lasting more than one year than in the group with complaints
lasting less than one year (44.2% vs. 31.2%). All three tests performed better in
the patients who had had dysepsia for at least one year (Table 3 and Figure 1).
The PPV dropped from 94.1% to 82.6% for the CUBT and from 94.7% to 75%
for the ELISA test in the subgroup of patients who had dyspeptic complaints
lasting less than one year.
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Discussion
In contrast to previous research, we evaluated the test performances of three
non-invasive  H pylori    tests   (whole blood test,   CUBT,   ELISA)  in  the  same
primary care population and compared their results with those of two invasive
reference tests (CLO™ test, histology). Both the CUBT and ELISA proved
effective in the primary care setting. This is in line with other similar validation
studies that have been performed in primary care.13,14,16,17 We also confirmed
earlier reports of the inferior test characteristics of the whole blood test when
used in daily practice.10,11 The debate on which invasive test is most suitable for
use as the “gold standard” reference test has been influenced by different
experiences of gastroenterologists and microbiologists. In our study, both
invasive tests (CLO™ test and histology) had similar test characteristics and
the validation did not differ. This is also in line with other studies on these
reference tests.18-21 Both the CUBT and ELISA performed well in this study.
Their applicability in daily practice, however, differs. For the CUBT, for
example, one needs a facility were patients can stay for half an hour to perform
the two sessions of the breathtest. Further, the current logistics for the
performance and analysis of the CUBT are not ideal in the Netherlands: e.g.,
the reading/analysis of the CUBT is performed in batches, which means that
the results are not directly available, and an expensive mass spectrometer is
required for the analysis (this instrument is presently available in only a few
centers). In contrast, the ELISA can be performed in most GP laboratories
throughout the country and a good infrastructure exists for both the analysis
and the rapid reporting of the ELISA test results. This can be very important
since the choice of treatment for dyspepsia (either acid-suppressive drugs or
eradication therapy) often depends on the results of a non-invasive H pylori test
and it is desirable that these test results are available as soon as possible. The
CUBT does, however, have the advantage that it can be used to follow up
patients who have recently undergone eradication therapy. In contrast, the
ELISA needs 3-6 months before it can monitor seroconversion.
From a cost-effective point of view, it must be noted that the CUBT is three to
four times more expensive than the ELISA (the costs to perform and analyse is
about EURO 11 for an ELISA and EURO 45 for the CUBT). Moreover, there is
no national refunding arrangement currently available in the Netherlands for
H pylori testing via CUBT, which obviously creates differences in diagnostic
possibilities. The ELISA, on the other hand, is refunded nationwide.
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In general dyspepsia studies which include referral for endoscopy are prone to
selection bias at inclusion. However, we have the impression that this was not
a major problem in our patient population. The endoscopic results of our study
population  were actually quite comparable to those in the study performed by
Heikkinnen et al, in which  four hundred unselected consecutive patients
presenting with dyspepsia in general practice were referred for endoscopy.2
Next to that the H pylori infection rate (which could be considered as a second
indicator of referral bias) that we found is in line with that in other primary
care studies.4,22 Therefore we think that our study population was a good
representation of the dyspeptic patient population in primary care. We used
the test results found at endoscopy as our reference standard. The histological
results were obtained by routine pathological examination. The way we
interpreted the test results was a reflection of routine practice; however, there
might have been different readings of the same sample if they had been “read”
by different pathologists.
By re-evaluating the test characteristics in relevant clinical subgroups, we tried
to illustrate the importance of taking into account the target patient group
when choosing the optimal test. For example, the infection rate was higher in
the subgroup of patients who suffered from dyspepsia for more than one year.
In fact, there was a trend that all of the tests showed a better performance in
this subgroup. This may be explained by the higher prevalence of H pylori
infection found in these patients. Although these results still need
confirmation, they might have implications for future diagnostic strategies. The
declining prevalence of H pylori in dyspeptic patients in the Netherlands might
result in a lower specificity and PPV of the ELISA. If this should occur, the
ELISA might be less appropriate for screening purposes in dyspeptic patients;
i.e., a positive test result will no longer reliably confirm infection. The results of
future studies that look at test performances in other dyspepsia subgroups
(e.g., type of complaints, ethnicity, etc.) might give rise to a differentiated
advice for different groups.
There is growing evidence regarding the efficacy and cost-effectiveness of
testing and treating H pylori infections in patients with peptic ulcer disease.23
The role of H pylori in non-ulcer dyspepsia, however, is still not clear, although
recent studies suggest that treating the infection in this group might be cost-
effective.24 Regardless of the chosen strategy, it is essential for the GP to have a
fast and reliable test for screening for H pylori infections. We recommend that
GPs use either the ELISA or the CUBT, depending on local availability and
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costs. In the future, this advice might need further differentiation if H pylori
infection rates continue to decline.
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Abstract
Helicobacter pylori (H pylori) plays a major role in peptic ulcer disease and as a
result testing for H pylori infection in patients with dyspepsia has often been
advocated. Aim of the study was to determine the diagnostic accuracy, the
analytical performance, and optimal cut off point of a new serological assay,
the Pyloriset® EIA-G III for the detection of H pylori infection in the primary
care setting. For 113 primary care patients with dyspepsia urea breath test,
CLO™test, histology and serology tests were performed. Diagnostic accuracy
of the Pyloriset® EIA-G III was evaluated against a reference standard of a
carbon urea breath test (CUBT), CLO™ test and histology (from gastric
biopsies). Precision, linearity and correlation of the serological assay with the
CUBT and former Pyloriset® were also determined. At the optimal cut-off level
of 40 U/ml the positive predictive value was 92.1%, negative predictive value
96.3%, sensitivity 87.5%, and specificity 93.9%. The within-run precision was
high. The recovery data were good. The correlation of both CUBT and the
former Pyloriset® EIA-G and the Pyloriset® EIA-G III was high. At the cut-off
level of 40 U/ml the new Pyloriset® EIG-G III is a reliable method to detect H
pylori infection in the primary care setting.
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Introduction
The bacterium Helicobacter pylori (H pylori) is known to play a major role in the
development of peptic ulcer disease. Infection with this spiral, urease
producing bacterium causes histological gastritis and is an important risk
factor for the development of gastric adenocarcinoma and lymphoma.1-4
Screening the whole general population for infection with H pylori does not
appear to be cost-effective, but case finding in certain risk groups, i.e. patients
with active ulcers, a history of ulcers, or gastric mucosa-associated lymphoid
tissue lymphoma is indicated.5,6
Many invasive and non-invasive methods are available for the detection of H
pylori infection. Invasive methods require an endoscopy to obtain biopsies of
gastric tissue, in which H pylori can be diagnosed by urease activity, histology
or culture of the bacterium. Endoscopy is an inconvenient and expensive
method of H pylori testing (approximately EURO 250 per endoscopy including
invasive H pylori testing) and reliable non-invasive methods could be of great
help, notably in the primary care setting. Non-invasive techniques to detect
bacterial infection include carbon urea breath tests (CUBT), antigen stool tests
and anti-H pylori antibody detection by serological methods.7,8 The antigen
stool test is promising but needs further validation in different patient settings.
The 14C-UBT is a simple and reliable test, but the radioactive component
restricts its practical use. The 13C-UBT does not have the disadvantage of
radioactivity, but requires the availability of an expensive mass spectrometer,
resulting in a total cost of EURO 45 per 13C-UBT (personnel, equipment and
materials). The test characteristics of most office tests, such as whole blood
tests, are disappointing. 9,10
A fast and reliable test method to diagnose H pylori infection is to test for
antibodies to the antigen of H pylori. The enzyme immunoassay is the most
commonly used serological test, because it is a reliable, fast and low cost
technique (per test approximately EURO 11 for personnel, equipment and
materials). Many serological kits for the detection of H pylori-specific IgG
antibodies are now commercially available.11,12 Aim of this study was to
investigate the analytical performance and reliability of a new serological
assay, the Pyloriset EIA-G III, for the detection of H pylori infection in the
primary care setting. We investigated its test characteristics and analytical
performance against a reference standard of CUBT and invasive tests, and
against the former Pyloriset,® and determined the optimal cut off level for the
new test.
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Methods
Patients
Patients were recruited from general practices in the city of Utrecht, the
Netherlands. Eligible for the study were patients that presented themselves to
their GP with dyspepsia lasting at least two weeks and were ≥18 years old.
Pregnant patients and patients with pulmonal or cardiac comorbidity were
excluded. The patients were referred to the local primary care laboratory for
serological screening for H pylori infection (Pyloriset® EIA-G and Pyloriset®
EIA-G III, Orion Diagnostica, Espoo, Finland). At the same visit the patients
also underwent a 13C urea breathtest test (Pylobactell™, BSIA/Torbet
laboratories, Chatham, United Kingdom); the breathtest samples were
analysed and results expressed as 13CO2/12CO2 concentrations (an increase in
13CO2/12CO2, concentrations from baseline of more than 3.5 ‰ was required
for an established H pylori infection). Subsequently, patients were referred to
the local hospital for endoscopy, during which biopsy samples were taken for
histology (using Giemsa or Haematoxylin/Eosin stain), and a rapid urease test
(CLOTM, Australia).
Diagnosis with Pyloriset EIA-G III
The newly developed EIA kit, Pyloriset EIA-G III assay uses microtiter wells
coated with inactive H pylori antigens. In the present study, the assay
procedure steps were automated using the Biolab 300 (Meridian diagnostics,
Cincinnati, USA). Serum samples were diluted (1:201) with serum dilution
buffer. Four undiluted calibration sera and diluted samples were added to the
wells, mixed, and incubated at 25°C for 30 minutes. The plate was washed
three times with washing buffer, and then conjugate (peroxidase conjugated
anti-human IgG (rabbit)) was added to each well. After mixing and a second
incubation at 25°C for 30 minutes, the plate was washed again. Substrate
(3,3’,5,5’-tetramethylbenzidine) was then added to each well and the plate
mixed and incubated at 25°C for 10 minutes. The reaction was stopped by
adding the stopping solution (1M H2SO4) and the absorbance of the assay was
read at 450 nm. The optical densities of four reference standards were used to
plot a standard curve (straight line) by which the H pylori IgG antibody levels
in patient samples were quantified. The results were expressed in arbitrary
units per milliliter. Reference standards 1 to 4 represent 10, 20, 120, 640 U/ml,
respectively. The absorbance readings are proportional to the logarithm of the
antibody concentration. Following the manufacturer’s interpretation of the
assay the result should be considered positive for H pylori antibodies if the
U/ml of the serum is equal or higher than that of the calibrator serum 2 (≥20
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U/ml). To compare the new with the former H pylori assay, the arbitrary units
were multiplied with a factor 10 (recommended by the manufacturer) to reset
these values in titer values as used in the former Pyloriset EIA-G new kit. The
total procedure time for the Pyloriset  EIA-G III was 80 minutes.
Definition of the reference standard
Patients were considered to be H pylori infected if at least two of the following
three tests were positive: 1) rapid urease test (CLOTM), 2) 13C urea breath test
(CUBT), 3) histology.
Analytical performance of the Pyloriset® EIA-G III
Precision
Within-run precision was determined using sera on three levels. Replicate
measurements (n=20) were performed in one run for each level. This procedure
was processed using a single reagent lot. The within-run precision data are
expressed as coefficients of variation (CV,%). Between-run precision was
determined using sera on three levels. Replicate measurements (n=5) were
performed in different runs. A single reagent lot was used during the
measurements. The between-run data were expressed as CV’s.
Linearity
The linearity of the Pyloriset® EIA-G III was assessed by calculation of the
recovery of a repeatedly diluted high concentrate sample (∼800 U/ml).
Effect of re-thawing sera on detection witH pyloriset® EIA-G III
The possible effect of re-thawing sera on the IgG antibody levels was tested
with sera at 3 levels. The sera have been thawed and frozen again for 5 times
and analyzed. The possible effect of re-thawing is expressed as CV.
Correlation of tests
Correlations between the qualitative test results (i.e. positive or negative) of the
Pyloriset® EIA-G III with the CUBT, and Pyloriset® EIA-G new were
determined using Cohen’s kappa (measurement of agreement).
Statistical analysis
The test characteristics were reported in terms of sensitivity, specificity,
positive and negative predictive values. Measurement of agreement was
reported in terms of Cohen’s kappa. Statistical analysis was performed using
SPSS version 9.0 for Windows.
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Table 1   Characteristics of the Pyloriset® EIA-G III at different cut-off levels
in relation to the reference standard (95% confidence interval)
Cut-off level
20 30 35 40
PPV 69.8 (55.7-81.7) 78.7 (64.3-89.3) 83.7 (69.3-93.2) 92.1 (78.6-98.3)
NPV 98.5 (92-100.0) 98.6 (92.6-100.0) 97.4 (90.9-99.7) 96.3 (89.4-99.2)
Sensitivity 97.4 (86.2-99.9) 97.4 (86.2-99.9) 94.7 (82.2-99.4) 87.5 (73.2-95.8)
Specificity 80.5 (70.3-88.4) 87.8 (78.7-94.0) 91.5 (83.2-96.5) 93.9 (86.3-98.0)
PPV: positive predictive value, NPV: negative predictive value
Results
Patients
Between April 1999 and January 2000, 133 primary care patients with
dyspepsia were included, and referred for H pylori testing and endoscopical
diagnosis. For 113 patients complete data on both the EIA and the reference
standard were available. The H pylori infection rate, according to the reference
test (consisting of CUBT, CLO and histology), was 31.7%.
Validation against reference standard
The observed negative and positive predictive values, sensitivities and
specificities of the Pyloriset® EIA-G III assay are given in table 1. Test
characteristics were determined at different cut-off levels (above which an
individual was considered to be H pylori infected). At cut-off levels for
infection varying from 20-40 U/ml, positive predictive values ranged from
69.8-92.1%, negative predictive values from 96.3-98.6%, sensitivities from 87.5-
97.4%, and specificities from 80.7-93.3%.
Table 2 Table demonstrating the results of dilution in terms of recovery
using the Pyloriset® EIA G III
Dilution Value (U/ml) Recovery (%)
A 806 100
A/2 360 89
A/4 179 99
A/8 75 84
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Table 3   Percentage of patients incorrectly diagnosed in a population with H
pylori infection rate of 40% at different cut-off levels
Cut-off level
20 30 35 40
False positives 9 6 5 2
False negatives 1 1 2 3
Analytical performance of the Pyloriset® EIA-G III
Precision
The within-run precision data expressed as CV’s of  the mean levels of 10
U/ml, 133 U/ml and 503 U/ml were respectively 1.6, 8.4 and 11.2%. At the
mean levels of 11 U/ml, 93 U/ml and 614 U/ml, the between-run precision
CV’s were 4.8, 7.5 and 28.7% respectively.
Linearity
The calculated recovery data are shown in table 2. Good linearity data were
observed, with recovery data above 80% for all the 2, 4 and 8 times dilutions.
Effect of re-thawing sera on detection witH pyloriset® EIA-G III
The CV’s measured for the samples at mean levels of 10.5, 162 and 892 U/ml,
that had been thawed and frozen again, were respectively 3.4, 13.5 and 28.4 %.
Correlation of tests
The correlation (comparing qualitative test results) between the breath test and
Pyloriset® EIA-G III was high: Cohen’s kappa of 0.92. This result was similar
for cut-off levels of 35 or 40 IU/ml for the Pyloriset® EIA-G III as level of
proven infection. The correlation between the former Pyloriset® EIA-G and the
Pyloriset® EIA-G III was high; Cohen’s Kappa of 0.97 or 0.98 (using cut-off
values of 40 U/ml or 35 U/ml respectively).
Discussion
The new Pyloriset® is a reliable method to detect H pylori infection in primary
care. Test characteristics validated against a high quality reference standard are
excellent, and correlation of results with those of CUBT and the former EIA is
good. The recommended cut-off value needs to be carefully reconsidered. The
78                                                                                                                        Chapter 5
cut-off value of the former Pyloriset® assay as given by the manufacturer was a
titer of 300. Surprisingly for the Pyloriset®  EIA-G III assay, a cut-off value of 20
U/ml is recommended by the manufacturer, where a value of 30 U/ml was
expected according to the factor 10 difference between the two assay’s. For use
in clinical practice, supporting clinical decisions for individual patients, the
optimal cut-off point should be guided mainly by the positive and negative
predicted value of the test (the PPV and NPV). The fact that H pylori diagnosis
will be mainly used in dyspepsia management to support ulcer detecting
strategies (in particular endoscopy plus antibiotic treatment), puts even more
emphasis on the need for a correct H pylori test result, both positive and
negative. Calculating the percentage of incorrectly diagnosed or missed H
pylori infections at different cut-off levels demonstrates the most efficient cut-
off point in clinical dyspepsia management in primary care (table 3). At 40
U/ml only 5% of the patients are incorrectly diagnosed.
Validation of the former assay (Pyloriset®  EIA-G New) in a similar primary
care population resulted in a sensitivity of 91% and specificity of 78%.13 We
used a more solid reference standard (at least 2 out of 3 reference tests positive,
versus only one reference test used by Lewin-van den Broek), which resulted
in a sensitivity of 94.7% and specificity of 92.7%. The new assay (EIA-G III)
performs in a similar way in terms of sensitivity, specificity, positive and
negative predictive value as the former EIA-G New.
A few additional advantages of the new EIA should be addressed. The total
procedure time of the EIA-G III is 80 minutes vs. 160 minutes in the EIA-G
New. In contrast to the former EIA, the EIA-G III has a straight calibration line,
which leads to accurate results in the whole calibration range. No
disadvantages in comparison with the former Pyloriset® could be found.
In conclusion this new serology assay is an accurate, reliable and inexpensive
screening test for H pylori infections in dyspeptic patients in a primary care
population, but the cut-off level for use in primary care should be increased
from 20 to 40 U/ml.
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Abstract
Objectives: To evaluate whether adherence to a new dyspepsia guideline
introduced in a group of general practitioners (GPs) receiving education or a
financial incentive is higher than in a control group not receiving a specific
intervention.
Design: Randomised controlled trial.
Participants: 28 GPs from 6 different GP groups and 260 dyspeptic patients
presenting in primary care.
Main outcome measures: Adherence to the new dyspepsia guideline as
primary outcome, quality of life and dyspepsia scores of the patients as
secondary outcome measurements.
Results: After adjustment for non-included patients, adherence to the guideline
was highest in GP group receiving an educational approach (49%). Adherence
to the guideline in the GP group receiving a financial incentive was similar to
the control group (32 vs. 34%). After adjustment for confounding and potential
clustering, the secondary outcome measures quality of life and dyspepsia score
did not differ between the patients from the three GP groups. The costs per
dyspeptic patient spent in the three GP groups varied and were lower in the
financial incentive group.
Conclusions: An educational approach leads to a higher adherence to a new
guideline compared to a control group. A financial incentive did not have a
positive effect on the adherence to the guideline, although the costs related to
the dyspepsia were somewhat lower. The effect of implementing a new
guideline by means of an approach combining education with a financial
incentive should be explored.
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Introduction
Scientific knowledge develops rapidly and relevant research findings have to
be introduced to healthcare professionals, so that they can be applied in daily
practice. For this reason, guidelines are developed in order to assure an
adequate approach to patients presenting with the same problem. Many
guidelines on a large variety of medical problems have been developed. The
scientific content of guidelines receives ample attention, but the features of
guidelines that may determine their dissemination in daily practice remain
largely unknown.1
In the Netherlands, roughly 60% of the recommendations in primary care are
followed.2 A study by Grol et al., analysing adherence to more than 10
guidelines for primary care, pointed out that if the recommendation was
controversial or not compatible with current values, low adherence was found.
Many different methods to implement guidelines exist, including educational
approaches, reminders, audit and feedback, use of local opinion leaders, local
consensus processes and patient-mediated interventions.3 The effect of these
interventions has been widely studied, but systematic reviews have provided
conflicting results about their effectiveness.4,5 This is partly attributable to
methodological flaws of many studies, in particular lack of control groups and
randomisation. So far, individual instruction, feedback and reminders seem to
be the most effective single strategies in guideline implementation,6 while
combinations of interventions seem more effective than single ones.7
Interestingly, several approaches to optimise guideline implementation such as
peer review, practice support and incentives have been studied less frequently.
In particular, the influence of financial incentives remains unknown. We
compared the adherence to a new guideline on dyspepsia in primary care in
the Netherlands in GPs receiving an educational approach and GPs receiving a
financial incentive with GPs receiving no specific intervention. Subsequently
we assessed the effects of these interventions on the patients with respect to
quality of life and dyspeptic complaints.
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Methods
A newly developed guideline with a focus on the diagnosis and treatment of
peptic ulcer disease (PUD) was introduced to 28 general practitioners (GPs)
from six different GP groups in the Netherlands. Aim of the guideline is to
assist the GPs in management of dyspepsia based on the medical history and H
pylori infection status.8
In a cluster randomised trial the six groups of GPs were randomly allocated to
one of two interventions: education, or financial incentive, or a control group.
The guideline
The new guideline consisted of two consecutive steps in the approach of
dyspeptic patients consulting the GP, including patient history, H pylori
diagnosis and subsequent treatment.
The first step involved risk estimation, based on history taking, for PUD by the
GP. For each individual consulting the GP because of dyspepsia, GP filled in a
form that contained three questions regarding dyspepsia: 1. Does the patient
have a history of PUD? 2. Does the patient smoke? 3. Does the patient have
pain on an empty stomach? The questions were answered with “yes” or “no”.
For patients at high risk for PUD (i.e. two or more questions were answered
with “yes”), the GP was requested to perform a H pylori test (via serological
immunosorbent assay or with a 13carbon urea breath test). In low risk patients
(i.e., less than two questions answered with “yes”), GPs were requested to
prescribe H2-receptor antagonists (H2RAs) or prokinetic medication. The
second step in the approach involved the correct interpretation of the results of
the first step: H pylori infected individuals at high risk for PUD should receive
eradication therapy (triple therapy) for H pylori, and all other individuals
should receive H2RAs and/or prokinetic therapy (as recommended by the
Dutch College of General Practitioners’ dyspepsia guideline).9
Interventions
The education group received specific training in dyspepsia management
during two sessions. In the first session general information was presented to
the whole group, and the second session focussed on individual feedback for
the participating GPs.
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The financial incentive group received a bonus of EURO 11 for every patient
managed according to the new dyspepsia guideline. No extra instruction or
training was involved.
The control group received no specific intervention; only written instruction on
the new guideline was provided. This is the usual way that a new guideline is
introduced in primary care in the Netherlands.
Patients
Patients were eligible to participate in the study if they consulted their GP
because of a first or a new episode of dyspepsia. They had to be 18 years of age
or over and had to be capable of filling in the requested forms in the Dutch
language. Exclusion criteria were alarm symptoms (dysphagia, haematemesis,
blood in stools, unintentional weight loss etc.), and H pylori eradication therapy
in the past.
Outcome
The primary outcome of the study was the percentage of patients in the three
GP groups treated correctly according to the new dyspepsia guideline. This
was evaluated using data on the adherence to the guideline in both the first
and the second step. The first step was checked by comparing the answers
given to the three questions for the PUD risk estimation on the form filled in by
the GP and subsequent H pylori testing. The latter was assessed by scrutinising
the GPs’ electronic medical record of the patients. The second step, which
involved the correct interpretation of the risk estimation and subsequent
medical treatment, was also evaluated using the electronic medical records: all
information on diagnostic tests, referral, and prescription of medication for
dyspepsia was collected.
As secondary outcome measures, dyspeptic symptoms and quality of life of the
patients were evaluated. Dyspeptic complaints of the included patients were
measured at the first consultation and after three months using a validated
questionnaire on dyspepsia.10 Quality of life was measured using
COOP/WONCA charts at the first consultation and at three months after the
initial visit.11 In addition, medical consumption of all patients was measured
using the databases from the GP. The costs of prescriptions related to the
dyspepsia, referrals to specialists, diagnostic tests (X-rays, ultrasound,
laboratory test and H pylori tests) and number of consultations in the three
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month time-period following the initial consultation were calculated. The costs
of the specific training of the GPs (2000 EURO overall) and the financial
incentive per patient (EURO 11) included in the study were also taken into
account. Thus, costs per patient related to dyspepsia in the three GP groups
were calculated and compared.
Dyspepsia incidence measurement and estimation of non-inclusion in three
GP groups
Three months prior to the intervention, the GPs registered all patients
presenting with dyspepsia in order to evaluate whether there were differences
in dyspepsia incidence between the three GP groups. In one randomly selected
practice from each trial arm we identified all dyspeptic patients during the
intervention period from the electronic medical files. We asked the GP to
indicate the reason for non inclusion for each of the dyspeptic patient that was
not included in the study, and an estimate was obtained of the percentage of
eligible patients that was not included in the study (no form was filled in by
the GP). Based on these findings, the adherence to the guideline was adjusted,
taking into account the number of patients not included in the study and
assuming that non-inclusion of a patient meant non-adherence to the guideline.
Statistical analysis
For the primary outcome measure, adherence to the guideline, multivariate
logistic regression analysis was applied to adjust for potential confounding
variables, notably age and gender of the patients, history of dyspepsia, and
quality of life of the patient at first presentation. The adherence to the guideline
was adjusted for non-inclusion of patients. Subsequently, multilevel analysis
was performed to take into account the potential clustering of patients
included by the same GP.
For the secondary outcome measures dyspepsia score, quality of life and costs
related to the dyspepsia, linear regression analyses was performed. Analysis of
variance (ANOVA) was used to compare the reported scores after three
months between the three GP groups, while adjusting for baseline levels of
these parameters and confounding where appropriate. Multilevel analysis was
performed to adjust for potential clustering.
Statistical analyses were performed using SPSS version 10.0 for Windows and
the MIXOR statistical package (program for mixed-effects ordinal regression
analysis).
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Sample size
Our study was designed to detect a difference of 20% in adherence to the
guideline between the control group and both intervention groups. Given an
estimated adherence to the guideline of 60% in the control group, an alpha of
0.05, and intracluster correlation of 0.05, 80% statistical power and 28 GPs, an
average number of 8 patients per GP was required.
The study was approved by the medical ethics committee of the University
Medical Center Utrecht and written informed consent was obtained from all
participating patients.
Results
From July 1 2000 till July 1 2001, 260 patients with dyspepsia were recruited by
the 28 participating GPs. Patients characteristics with respect to age, gender
and medical history are reported in table 1.
In the education group the GPs correctly applied the new guideline in 63% of
the patients, while the adherence in the financial incentive and control group
was 63% and 67% respectively (p-value 0.82). Taking into account potential
confounding variables did not materially influence these unadjusted findings
(Table 2).
As we could have expected because of the randomisation procedure, no
differences  in  dyspepsia  incidence  levels  were detected  in the  three months
Table 1  Patient characteristics of the 260 dyspeptic patients presenting in
primary care that were included in the study
GP intervention group
Education
n=99
Financial
incentive
n=73
Control
group
n=88
Overall
n=260
Male % 42.6 41.3 31.8 38.4
Age (mean) 47.2 50.4 45.8 47.6
History of dyspepsia % 66.3 64.2 66.3 65.7
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Table 3 Effect of a financial incentive or an educational approach versus the
control group on several outcomes at the patient level
Dys 3 p-value
unadjusted
p-value
adjusted‡
WONCA 3 p-value
unadjusted
p-value
adjusted‡
Education 6.5 0.70 0.48 14.4 0.47 0.40
Financial
incentive
4.9 0.05* 0.07 13.4 0.52 0.29
Control
group
6.6 13.9
Dys 3: dyspepsia score after three months, WONCA 3: COOP/WONCA charts score
after three months
‡ potential confounders: age, sex and prior dyspepsia of the patient
(p-values analysed using ANOVA analysis, comparing the two intervention groups
with the control group)
period before the intervention. The number of patients included per GP in the
one-year intervention period varied per GP group: on average 8 patients were
included per GP in the control group and in the group receiving a financial
incentive, and on average 12 patients were included per GP in the group in
which an educational approach was taken. Non-inclusion based on the
telephone survey was estimated at 30% in the GP group with the highest
number of included patients. Thus, a mean number of eligible patients per GP
in the education group of 18 (12 x 100/70) was assumed and the adjusted
estimations of the adherence to the guideline in the education group was 49%.
Assuming a similar incidence of dyspepsia in the three GP groups (of 18 per
GP per year), the adjusted adherences to the guideline in the financial incentive
group and control group were 32 and 34% respectively (Table 2). The
intracluster correlation was low (0.07), multilevel analysis did not affect the
adjusted guideline adherences.
Three months after the visit to the GP, the dyspepsia score was lowest in the
financial incentive group (p=0.05). After adjustment for baseline dyspepsia
score and potential confounders, however, no differences were observed (Table
3). No differences in the quality of life scores were observed in the three
compared groups.
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Table 4 Medical interventions and costs per patient in the three GP groups.
Education
(n=99)
Financial
incentive
(n=73)
Control
group
(n=88)
Overall
(n=260)
Consultations in three months 1.9 1.7 2.0 1.9
Endoscopies (%) 14.3 8.2 18.2 13.9
Referral rate (%) 8.2 4.1 0 4.2
Diagnostic tests (%) † 10.1 15.1 21.6 15.4
H pylori tests (%) ‡ 36.4 17.8 25.0 27.3
% patients receiving medication 91.9 93.2 96.6 93.8
Costs per patient in EUROs 220.0 172.0 218.0 205.9
† X-ray, ultrasound, laboratory tests (kidney and liver parameters)
‡ Serology (enzyme linked immunoassay) or 13C urea breath test
The mean costs per patient with respect to the dyspepsia management in the
three groups were EURO 172 in the financial incentive group, EURO 218 in the
control group and EURO 220 in the combined education group (p-value 0.08)
(Table 4). Adjustments for potential confounders and multilevel analysis did
not change these findings.
Discussion
In this study we evaluated adherence to a new dyspepsia guideline in three
groups of GPs that were randomly allocated to receiving education or a
financial incentive or a control group not receiving a specific intervention. The
adherence to the guideline was highest in the GP group receiving education
(49%), and no difference in adherence was found between the GPs receiving a
financial incentive or the control group (32 vs. 34%). No clear differences in
dyspepsia or quality of life scores after three months or in the costs was
observed, although the costs made for the dyspepsia management in the
financial incentive group were lower than in the other groups.
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Several limitations of our study should be addressed. We assumed that for
dyspeptic patients not-included in the study the guideline was not followed.
We contacted a random sample of three GPs from the three GP groups by
phone to ask for reasons for not including patients for the study. The most
common answers given were lack of time of the GP, simply forgotten to ask the
patient to participate and low expected compliance of the patient to fill in the
questionnaires. The exact number of patients not included in the study could
not be calculated, but only estimated on the data provided by the random
sample of GPs.
Obviously, our method of adjusting the adherence to the guideline could be
criticised. Our underlying assumptions (the estimated 30% non-inclusion in the
education group, similar incidence of dyspepsia in the three GP groups and
considering non-inclusion as non-adherence) seem reasonable, and no
consensus exists to how these adjustments should be performed. We recognise
that in particular the assumption that in 100% of non-included patients the
guideline was not followed could be an overestimate. If in a considerable
proportion of non-included patients the guideline was indeed followed, the
adherence in all three GP groups would increase to a similar extent, since it is
unlikely that this proportion would differ between the groups of GPs.
Interestingly, in the vast majority of similar studies, non-inclusion of patients is
not taken into account, despite the potential influence on the adherence
estimates. In our view, more attention should be paid to this methodological
issue.
To our knowledge, this is the first study that evaluated the effect of a financial
incentive on adherence to a new guideline. So far, studies have evaluated the
effect of rewarding of GPs based on their prescribing habits.12,13 The GPs in our
intervention group were rewarded for every patient treated in accordance with
the new guideline. The incentive, EURO 11, may have been too low to confer
the optimal effect. In relation to a normal consultation fee in primary care in
the Netherlands of EURO 18, and the extra time a GP needs to include a patient
in a study protocol and subsequent diagnostic and therapeutic procedures, the
reward was, however in line with the actual time invested by the GP.
We expected that the number of patients included by the GPs stimulated by a
financial incentive would have been higher than in the control group.
However, in our study, money did not affect the inclusion rate. One might
argue that the height of the incentive did not encourage GPs to include more
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patients, and that a higher reward would have had an effect on the inclusion
rate. A higher reward, however, would lead to higher costs related to the
dyspepsia management in the financial incentive group, as this reward for
correct adherence to the guideline would also have to be taken into account.
The lower costs related to the dyspepsia management in the group stimulated
by a financial incentive would than most likely disappear.
As there is evidence that combined strategies have a greater impact on the
success of implementation strategies, the effects of implementing a guideline
on dyspepsia or other patient domains by means of an educational approach in
combination with a financial incentive should be explored.
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General discussion and recommendations
In the first part of this thesis diagnostic studies on H pylori management in
patients with dyspepsia in primary care are presented. The second part of the
thesis describes the implementation of a new dyspepsia guideline with a focus
on peptic ulcer disease (PUD) diagnosis and treatment. In order to achieve a
better adherence to the new guideline, we tested the potential additional value
of two interventions (financial incentive and educational approach). From each
chapter the key messages are stated below. The results of the studies are
discussed in the realm of available evidence. In addition, limitations of our
study are discussed. Finally recommendations for daily practice and future
research are given.
Key messages from this thesis
At present, H pylori does not play an important role in the management of
dyspepsia in primary care in the Netherlands. Of all patients with a history
of PUD, one third is not treated optimally. (Chapter 2)
Testing for infection with H pylori is not indicated in all dyspeptic patients
in primary care. In an easy to define group (based on three items from
history taking) at high risk for PUD, H pylori testing and subsequent
treatment is useful. (Chapter 3)
In primary care the serological test (ELISA) and 13carbon urea breath test
(CUBT) perform well. However, given the decline in H pylori infection rate
and subsequent poorer performance of the ELISA, the CUBT should be the
test of choice. Whole blood tests should be avoided due to poor
performance. The CUBT is feasible in primary care. (Chapter 4)
A newly developed immunoassay for the detection of H pylori infection, the
Pyloriset® EIA-G III, has good test characteristics in primary care, even at
low H pylori infection rate. (Chapter 5)
An educational approach is superior to routine introduction of a new
dyspepsia guideline in primary care with respect to adherence to that
guideline. The (modest) financial incentive we studied does not improve the
adherence to the guideline.  (Chapter 6)
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Comparisons with available evidence
Studies with respect to management of H pylori infection in primary care so far
have indicated that confusion exists among GPs on selection for testing,
treatment schedules, and management in case of persisting or recurring
symptoms.1-6 In Scotland a survey demonstrated that 56 different treatment
schedules were being used by GPs for eradicating H pylori, and that in only one
third of the patients receiving drugs for H pylori eradication, the GP actually
knew the infection status of the patient.6 Our study among Dutch GPs shows a
more consistent picture: H pylori plays a minor role in dyspepsia management
and GPs focus H pylori related management on patients with a history of PUD
or ulcer-like complaints. The GPs in the Netherlands use a rather uniform
eradication schedule. This might be explained by the strong influence of local
pharmacotherapeutic guidelines in the Netherlands. Most GPs are involved in
pharmacotherapeutic discussiongroups, in which they decide, together with
pharmacists and specialists, on an evidence based standardised regional
formularium. The triple therapy for H pylori treatment was incorporated by
many of these pharmacotherapeutic discussiongroups. The availability of
complete kits of triple therapy medication which are easy to prescribe by the
GP, and easy to use by patients most probably also influences the choice of
medication that is being prescribed. The pharmaceutical industry has actively
promoted the availability of these triple therapy kits. In addition national
guidelines exist with respect to treatment schedules for infections, resulting in
a low resistance pattern for antibiotics.
The low level of patients with a history of PUD treated for their H pylori
infection in the Netherlands is similar to results from GP studies in the United
Kingdom.6 This is the key topic that future training/education for PUD
management in primary care should focus on, as recurrences of silent ulcer
disease can often be prevented by case finding among patients on long term
acid suppression.
Identification of patients at high risk for having PUD based on signs and
symptoms has been a topic of interest for quite a while. In primary care such an
approach would be very useful, as referral for endoscopy of all patients is
unrealistic and would induce high costs. The development of symptom based
algorithms for the detection of peptic ulcer disease has, so far, given
disappointing results.7-15 The explanation for the poor performance of these
models lies mainly in the lack of statistical power due to small numbers of
available patients, missing data on potential diagnostic variables and
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shortcomings in the statistical analysis. In addition, history items may not be
able to distinguish between those with or without PUD. We showed that in an
easy identifiable high risk group H pylori testing improves the accuracy of
diagnosing PUD based on history taking. Some of our results are in line with
previous developed algorithms. In these studies a history of PUD and smoking
were also found to be a risk factor for PUD. However, we were the first to
report the results of a diagnostic model that evaluated the value of additional
H pylori testing in patients suspected of PUD.
With respect to validation of non-invasive H pylori testing, many studies have
been performed. These validation studies are essential, as tests are known to
have different test characteristics in primary and secondary care. This can be
explained by the fact that both the severity and prevalence of disease in
primary care differs considerably from secondary care, influencing both the
prior and post test probability of finding a particular disease. In addition,
trained hospital staff, performing diagnostic tests on a regular basis, may
guarantee better test methodology, resulting in better test characteristics in the
secondary care setting. The whole blood test, for example, performed poorly in
our study. This is in contrast with secondary care validations, but in line with
results from other studies in primary care.16-20 Validation under daily
circumstances provides a more realistic picture of the value of this test in
clinical practice. The test characteristics of the ELISA in our study are in line
with pooled results from other studies.21-22 Clearly the ELISA performs better
than the whole blood tests and is not as strongly influenced by the low
infection rate and low disease prevalence as the whole blood test is. The CUBT
had not been validated in a primary care population. Secondary care
evaluation results correlate strongly with our findings.23-26
Limitations of our studies
We already addressed some limitations of our studies in the different chapters
of this thesis. The diagnostic algorithm that was developed and described in
chapter 3 is based on data from three studies that were performed at our
department. Although the inclusion criteria for the three studies were similar,
selection of patients towards more serious disease might have taken place in all
of them. The fact that endoscopy was part of the research protocol
undoubtedly led to some form of inclusion bias; the prevalence of H pylori
infection and the symptom and disease severity may have been higher in our
subjects than in the dyspeptic patients at large. This may hamper the
generalisability of our results. However, endoscopy results in our study were
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similar to those found by Heikkinen et al., who reported endoscopy results of
400 consecutive unselected primary care dyspeptic patients.27 Therefore our
study population seems representative of dyspeptic patients presenting in
primary care, and we consider our algorithm suitable for use in the target
population of patients presenting with dyspepsia in primary care. Our
algorithm awaits external validation, and thus should be re-evaluated in
another primary care dyspeptic population.
We compared several non-invasive H pylori tests with a gold standard of
invasive H pylori tests. At the time of writing the study protocol in 1997, a
faecal antigen test for the detection of H pylori infection was not yet available,
so we did not include it in our comparison. Though this test awaits evaluation
in primary care, its test characteristics look similar to those of the CUBT. It
seems unlikely that the diagnostic performance of the faecal antigen test will be
better than the CUBT.
In our study on implementation of the diagnostic and therapeutic dyspepsia
guideline not all GPs used the electronic medical record to register patients
according to the international classification of primary care disease coding
(ICPC). Thus, the total number of dyspeptic patients eligible for the study was
difficult to assess. However, the dyspepsia incidence registration by the GPs
themselves did not reveal differences between GP groups, so the number of
patients expected to be eligible for the study during the one-year intervention
was equal. We did not have access to data of patients that were not included in
the study, so it was difficult to evaluate the reasons for non-inclusion. A
sample of GPs that we contacted via telephone and electronic medical records
that we studied indicated that the main reason for non-inclusion of the patients
were exclusion criteria as defined by us (notably patient not being capable of
filling in the questionnaires) and lack of time of the GP to ask patients to
participate in the study. The adjustment for the non-included patients that we
used to assess the adherence to the new guideline was based on the
assumptions that the incidence of dyspepsia was similar in the three GP
groups, that in non-included patients the guideline was not followed and that
the non-inclusion in the GP group that recruited most patients was 30%. There
was, however, no information whether in the non-included patients the new
guideline was indeed not applied, so our adjusted adherence data might be an
underestimation of the actual adherence in the three groups. We do not expect
the patient characteristics of the non-included patients to be different between
the GP groups, so the ratios of adherence between the three GP groups would
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be the same, thus justifying our conclusions.
Recommendations and future research
GPs should focus on patients at high risk for PUD and especially on those with
a history of PUD when applying H pylori testing and eradicating H pylori in
those infected. The method of case-finding for PUD in primary care both in
patients presenting with new dyspepsia and those requesting repeated
prescriptions of acid-suppressive drugs is not time consuming, but is (cost)
effective. A majority of dyspeptic patients with a history of PUD will be cured
when treated with an eradication therapy for H pylori; thus reducing costs
necessary for medication.
The CUBT has excellent test characteristics in primary care: it has high levels of
detection of H pylori infection, even at low infection rate. The CUBT can also be
used for immediate evaluation of successful H pylori shortly after termination
of this therapy. This is in contrast to the ELISA, where serum antigen levels of
H pylori remain high for up to 6 months, and follow-up at short notice remains
difficult. Even though currently the ELISA performs well enough, one can
expect that with the decrease of H pylori infection rate, its performance may
decrease to an unacceptable standard in the future. For this reason, the CUBT
should be the test of choice for H pylori testing in primary care with its low H
pylori prevalence, and should become available to all Dutch GPs. There is
enough evidence to reimburse the CUBT nation-wide provided that the test is
used for proper indications. We demonstrated that the logistics for proper use
of the CUBT could be arranged in co-operation with local primary care
laboratories. The relative high price per CUBT performed (EURO 45) will
undoubtedly drop if it is used on a larger scale.
As the group of non-ulcer dyspepsia patients is the largest subgroup of
dyspeptic patients in primary care, and meta-analyses based on treatment of
these patients with H pylori eradication therapy show modest or no
improvement with respect to dyspeptic symptoms, H pylori treatment in this
subgroup should not be recommended.28-38 However, the role of H pylori and
dyspepsia management in primary care might change in the future. The recent
reports on the relationship between H pylori infection and the development of
gastric cancer need further exploration specifically for the group of patients
with non-ulcer dyspepsia.39 In case the evidence for treatment of H pylori in this
group of patients in the prevention of the development of gastric cancer turns
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out to be cost-effective and clinically relevant, the recommendation for H pylori
management in these patients may need adjustment.
In general, more research to determine the diagnostic value of history taking
and subsequent diagnostic testing is necessary in order to demonstrate the
value of a stepwise approach in treating patients. Especially in primary care,
where history taking plays a major role in the distinction between disease and
non-disease, the diagnostic value of history taking should be evaluated so
evidence based recommendations for use in daily practice can be given.
Diagnostic tests should only be performed in patients where the result of the
diagnostic test has implications for the further management of that patient. The
patient’s history can be used to classify patients in subgroups at different risk
levels for that specific disease. Additional diagnostic testing in the high risk
group will raise the diagnostic accuracy of application of the test. In order to
use predictive models in daily practice, both internal (in the same population)
and external validation (the patient domain in which the model will be
applied) are required.40
Interventions for introducing guidelines in primary care have been studied
extensively. Single interventions sometimes proved to be less effective than
combined strategies. To our knowledge our study is the first to report the
comparison of an education strategy with a financial approach. As there is
some evidence that combined strategies have a greater impact on the
effectiveness of a new guideline, a combination of education and a financial
approach should be studied and compared to routine introduction of a
guideline in primary care.
In conclusion, the studies described in this thesis elucidated further the role of
H pylori infection in dyspepsia management in primary care. Patient subgroups
most likely to benefit from H pylori testing and subsequent treatment were
identified and additional evidence was provided on which diagnostic H pylori
test should be used in primary care. The implementation strategies we applied
to improve adherence to guidelines need further exploration. Notably the role
of an educational approach combined with a financial incentive should be
determined in more detail.
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Chapter one: introduction
In this thesis various studies on the management of patients presenting with
dyspepsia in primary care are described. Of all patients presenting with
dyspepsia, only a minority has organic disease. Roughly 25% of the dyspeptic
patients presenting in primary care is referred for endoscopy. At endoscopy,
relevant organic disease is found in 30-45% of the patients (5-15% peptic ulcer
disease and 25-30% gastro-oesophageal disease). Helicobacter pylori (H pylori)
infection is accepted as the most common cause of gastritis, and is
aetiologically involved in gastric ulcer, duodenal ulcer and primary gastric B-
cell lymphoma. For this reason, the role of H pylori diagnosis and treatment in
the management of peptic ulcer disease (PUD) has been a topic of interest in
research. Ideally, patients suspected of PUD should be tested for H pylori
infection without undergoing endoscopy. H pylori eradication is effective PUD
treatment and prevents relapses. Therefore, the diagnostic value of non-
invasive H pylori tests (i.e. tests not requiring an endoscopy) in PUD diagnosis
should be evaluated. In addition, the additional diagnostic value of H pylori
tests in patients at risk for PUD have to be determined. Finally, a guideline
based on the established diagnostic value of H pylori testing in dyspeptic
patients in primary care needs to be developed and introduced effectively in
medical practice.
The research questions answered in this thesis are:
• To what extent is H pylori diagnosis and treatment currently incorporated
in dyspepsia management in primary care in the Netherlands?
• What is the value of H pylori testing in addition to history taking in
diagnosing peptic ulcer disease in primary care?
• What is the optimal non-invasive H pylori test for diagnosis in primary
care?
• What is the diagnostic performance of a new immunoassay for the
detection of H pylori infection in primary care?
• Is compliance with a new dyspepsia guideline increased after introduction
by an educational or financial stimulus for GPs?
Chapter two: current dyspepsia management in primary care
A written questionnaire regarding various aspects of dyspepsia management
in primary care was sent to a random sample of 5% of all Dutch GPs. The main
topic of the questionnaire was H pylori diagnosis and treatment in dyspeptic
patients in primary care. Most GPs (± 80%) indicated they performed at least
one H pylori test in the past year. The vast majority of GPs (± 95%) prescribed H
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pylori eradication therapy in that same time period. Over 90% of the GPs
reported to use open access endoscopy services, enabling H pylori detection via
invasive methods. Of the non-invasive H pylori tests, serological tests were
most widely available (>50%). Whole blood tests and carbon urea breath tests
were hardly used according to the questionnaire. Patients with a history of
PUD, those on chronic acid-suppressive drugs and patients with recurrent
ulcer-like complaints were most frequently tested. Remarkably, GPs indicated
that of all patients with an active peptic ulcer only 75% received an eradication
therapy for H pylori infection. It was concluded that at present, testing for and
treating of H pylori plays a minor role in dyspepsia management in primary
care in the Netherlands.
Chapter three: H pylori diagnostic scoring rule
Aim of this study was to develop an easy applicable diagnostic scoring rule to
assess the presence of PUD in dyspeptic patients presenting in primary care.
Patients included in the study had had dyspeptic complaints for at least two
weeks. All patients underwent at least one non-invasive H pylori test and an
endoscopy, at which occasion biopsy specimens were taken for H pylori
determination. The presence or absence of PUD at endoscopy was considered
as the primary outcome of the study (“gold standard”). The univariate
association between each potential diagnostic determinant obtained from
history taking and the presence of PUD was quantified using odds ratios (OR).
All determinants with p-values smaller than 0.25 were entered in a
multivariate logistic regression model to evaluate which were independently
associated with the presence of PUD. The model was reduced by excluding
variables with a p-value greater than 0.05 in order to retain a simpler
diagnostic scoring model containing only the strongest diagnostic
determinants of the presence of PUD. With Receiver Operating Characteristics
(ROC) analysis, the diagnostic value of the model was evaluated.
Subsequently, a non-invasive H pylori test was added to the multivariate model
in order to evaluate its additional value for predicting PUD. Pre- and post-test
probabilities for PUD were calculated for all dyspeptic patients and for
subgroups of dyspeptic patients. For 565 patients we had complete data, and
38 of these patients had PUD. The three history variables that contributed most
to the prediction of PUD were history of PUD with an odds ratio (OR) of 5.5
(CI 2.6-11.8), pain on an empty stomach (OR 2.8, CI 1.4-6.0), and smoking (OR
2, CI 1.0-4.0). We allocated a score to each of these variables of respectively 2, 1
and 1. We were able to predict PUD by using this rule with and Area Under
the ROC Curve (AUC) of 0.71. Addition of a non-invasive H pylori test did not
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improve prediction of PUD (AUC 0.75, CI 0.66-0.83). However, in a subgroup
of patients at high risk for PUD (defined as having a score of two or more), the
H pylori test did add relevant information for diagnosing PUD, in that the pre-
test probability was 16% and increased to 26% after a positive test. We
concluded, that H pylori testing in all dyspeptic patients is not useful. However,
in a subgroup at high risk for PUD, preselected by medical history taking, an H
pylori test provides useful additional information.
Chapter four: validation of non-invasive H pylori tests
In this chapter three non-invasive H pylori tests were evaluated in order to
identify the most accurate and efficient test for diagnosing H pylori infection in
primary care patients. A whole blood test, an ELISA, and a 13carbon urea
breath test (CUBT) were validated against two different “gold standards”
based on results of gastric biopsies. The positive predictive value (PPV) of the
whole blood test was in the range of 71-75%, the ELISA 83-86%, and the CUBT
88-92%, while the negative predictive values ranged from 72-77%, 96-100%,
and 95-98% respectively. The sensitivity of the whole blood test was in the
range 36-42%, the ELISA 93-100%, and the CUBT 92-97%, while the specificities
were in the ranges 92-93%, 90-91%, and 93-95% respectively. We concluded
that both the ELISA and the CUBT are effective in the primary care setting.
However, at lower H pylori infection level, the ELISA performed poorer than
the CUBT, because of a diminishing PPV. It was concluded that the CUBT
should be the test of first choice for non-invasive H pylori testing in primary
care.
Chapter five: validation of a new EIA for H pylori infection
A newly developed immunoassay for the detection of H pylori infection, the
Pyloriset® EIA-G III, was evaluated in the primary care setting. The diagnostic
accuracy, analytical performance and optimal cut-off point were determined,
notably in a subgroup of patients with dyspeptic complaints lasting less than
one year. For 113 primary care patients with dyspepsia a CUBT, rapid urease
test, histology and serology tests were performed. Diagnostic accuracy of the
Pyloriset® EIA-G III was evaluated against a reference standard of CUBT, rapid
urease test and histology (from gastric biopsies). At the optimal cut-off level of
40 U/ml the positive predictive value was 92.1%, negative predictive value
96.3%, sensitivity 87.5%, and specificity 93.9%. The within-run precision was
high. The correlation of both CUBT and the former Pyloriset® EIA-G New and
the Pyloriset® EIA-G III was high. At the optimal cut-off level of 40U/ml the
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new Pyloriset® EIA-G III is a reliable method to detect H pylori infection in the
primary care setting.
Chapter six: implementation study
Based on the results of chapter three, we developed a clinical algorithm for
PUD detection and introduced it in primary care. We evaluated whether
adherence to the guideline introduced in a group of GPs improved after
introduction by means of an educational approach or a financial incentive
compared to routine introduction. Six GP groups were randomly allocated to
one of the three arms: education, financial incentive or control group. 28 GPs
from 6 different GP groups participated and enrolled 260 dyspeptic patients for
the study. Adherence to the guideline was evaluated as primary outcome (as
percentage of patients correctly treated according to the guideline); quality of
life and dyspepsia scores were used as secondary outcomes. After adjustment
for non-included patients, adherence to the guideline was highest in the GP
group receiving the education (49%). Adherence to the guideline in the GP
group receiving a financial incentive was similar to the control group (32 and
34% respectively). The secondary outcome measure quality of life and
dyspepsia score did not differ between the patients from the three GP groups.
The costs related to the treatment of the dyspeptic patients in the three groups
were similar, but lowest in the financial incentive GP group. Compared to a
financial stimulus, an educational approach led to a higher adherence to the
guideline, although the costs related to the dyspepsia were lower in the
financial incentive group. An educational approach turned out to be superior
to routine introduction of a new dyspepsia guideline with respect to adherence
to that guideline.
Chapter seven: general discussion and recommendations
The main results of the thesis are summarised in this chapter. Testing for H py-
lori infection is not useful in all dyspeptic patients presenting in primary care, it
should only be performed in an easy to define high risk group for PUD (based
on three items form history taking). In our view, the CUBT should be the test of
first choice for detecting H pylori infection in primary care. An educational
approach turned out to be superior to routine introduction of a new dyspepsia
guideline with respect to adherence to that guideline. The financial incentive
we studied did not improve the adherence to the guideline. Since there is
evidence that combined interventions have a positive effect on the adherence
to a guideline, the effect of implementing a guideline by means of an approach
combining education with a financial incentive should be explored further.
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Hoofdstuk 1: introductie van het proefschrift
Dit proefschrift beschrijft een aantal studies over patiënten die met
maagklachten de huisarts bezoeken. Van alle patiënten die zich met
maagklachten presenteren, heeft slechts een minderheid een aantoonbare
afwijking in de maag. Ongeveer 25% van alle patiënten die zich met
maagklachten bij de huisarts presenteren wordt verwezen voor een
gastroscopie. In 30-45% van deze patiënten wordt  relevante pathologie
gevonden (5-15% peptische ulcera en 25-30% gastro-oesophageale
refluxziekte). Helicobacter pylori (H pylori) infectie is de meest voorkomende
oorzaak van gastritis, en is tevens etiologisch betrokken bij de ontwikkeling
van maagzweren, zweren aan het duodenum en primaire B-cell lymfomen. Om
deze reden is de diagnostiek en behandeling van H pylori infectie bij patiënten
met mogelijk peptisch ulcuslijden onderwerp van studie. H pylori eradicatie is
een effectieve behandeling bij H pylori geassocieerd peptisch ulcuslijden en
voorkomt recidieven. Het testen op de aanwezigheid van H pylori zou bij
voorkeur niet-invasief (dus zonder gastroscopie) moeten geschieden. Daarom
is het belangrijk de diagnostische waarde van niet-invasieve H pylori testen in
de diagnostiek van peptisch ulcuslijden vast te stellen. Tevens zou de
toegevoegde waarde van een H pylori test bij patiënten met een verhoogd risico
op een peptisch ulcus onderzocht moeten worden. Deze informatie zou tot een
klinische richtlijn voor diagnostiek van ulcuslijden moeten leiden en
vervolgens optimaal geïmplementeerd moeten worden in de dagelijkse
praktijk.
De onderzoeksvragen die in dit proefschrift worden behandeld zijn:
• In hoeverre speelt diagnostiek en behandeling van H pylori infectie een rol
bij het huidige beleid bij patiënten met maagklachten in de eerstelijn?
• Wat voegt het testen op H pylori infectie toe aan de anamnese bij patiënten
die verdacht worden van een peptisch ulcus?
• Wat is de optimale niet-invasieve H pylori test in de eerstelijn?
• Wat zijn de diagnostische testeigenschappen van een nieuwe
immunoassay voor de opsporing van H pylori infectie in de eerstelijn?
• Is de navolging van een nieuwe richtlijn bij maagklachten in de
huisartspraktijk hoger in een groep huisartsen die hiervoor scholing of
geld ontvangt dan bij een controlegroep?
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Hoofdstuk 2: het huidige beleid van de Nederlandse huisarts bij
maagklachten en de rol van Helicobacter pylori diagnostiek
Om het huidige beleid van Nederlandse huisartsen bij patiënten met
maagklachten en de rol van diagnostiek en behandeling van H pylori daarbij
vast te stellen, werd een schriftelijke enquête gehouden onder een steekproef
van 5% van de Nederlandse huisartsen. De meerderheid van de huisartsen,
bijna 80%, gaf aan in de 12 maanden voorafgaand aan de enquête tenminste
éénmaal diagnostiek naar H pylori infectie te hebben verricht. Bijna 95% van de
huisartsen had in diezelfde periode H pylori eradicatiekuren voorgeschreven.
Meer dan 90% van alle huisartsen rapporteerden directe toegang te hebben tot
gastroscopie, waarbij invasieve H pylori bepalingen mogelijk waren. Van de
niet-invasieve H pylori testen, is de serologie (ELISA) het meest beschikbaar
voor huisartsen (ruim 50%). De vingerpriktest en de ademtest zijn zeer beperkt
beschikbaar. Patiënten met in de voorgeschiedenis een peptisch ulcus,
patiënten die langdurig maagzuurremmende medicatie gebruiken en patiënten
met recidiverende, ulcus-achtige klachten bleken het vaakst op H pylori infectie
te worden getest. Dat volgens de enquête slechts 75% van de patiënten met een
actief ulcus op H pylori infectie werd getest en behandeld is opmerkelijk te
noemen. Gebaseerd op deze gegevens werd geconcludeerd dat diagnostiek en
behandeling van H pylori infectie op dit moment maar een beperkte rol speelt
in het beleid rond maagklachten in de eerstelijn in Nederland.
Hoofdstuk 3: voorspellingmodel voor peptische ulcera en H pylori
diagnostiek
Het doel van deze studie was het ontwikkelen van een makkelijk toe te passen
predictieregel voor het opsporen van peptische ulcera bij patiënten die zich
met maagklachten bij de huisarts presenteren. De studiepopulatie bestond uit
patiënten die tenminste twee weken maagklachten hadden en daarmee  de
huisarts consulteerden. Alle patiënten ondergingen op zijn minst één niet-
invasieve H pylori test en tevens een gastroscopie waarbij biopten werden
afgenomen om H pylori infectie aan te kunnen tonen. De uitkomstmaat (d.w.z.
“gouden standaard”) van de studie was de aan- of afwezigheid van peptische
ulcera bij gastroscopie. De univariate associatie tussen alle potentiële
diagnostische determinanten afkomstig van de anamnese en de aanwezigheid
van een peptisch ulcus werd gekwantificeerd met behulp van odds ratios (OR).
Alle determinanten met een p-waarde kleiner dan 0.25 werden opgenomen in
een multivariaat logistisch regressiemodel om te beoordelen of zij
onafhankelijk geassocieerd waren met de uitkomst peptisch ulcus. Het model
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werd gereduceerd door alle variabelen met een p-waarde groter dan 0.05 uit te
sluiten. Op deze manier bleef een eenvoudiger diagnostisch
voorspellingsmodel over, waarin alleen de meest sterk voorspellende
variabelen aanwezig waren. Met behulp van Receiver Operating
Characteristics (ROC) analyses werd de diagnostische waarde van het model
geëvalueerd. Vervolgens werd de uitslag van de niet-invasieve H pylori test
toegevoegd aan het multivariate model, om de toegevoegde waarde ervan in
de voorspelling van peptisch ulcera te bepalen. De vooraf en achteraf kans op
peptisch ulcuslijden werd berekend voor alle patiënten en bepaalde
subgroepen. Van 565 patiënten beschikten wij over alle nodige variabelen, en
38 van deze patiënten hadden bij gastroscopie een peptisch ulcus. De drie
variabelen die het meest bijdroegen aan de voorspelling van peptisch
ulcuslijden waren: een voorgeschiedenis van een ulcus met een odds ratio (OR)
van 5.5 (betrouwbaarheidsinterval BI 2.6-11.8), hongerpijn (OR 2.8, BI 1.4-6.0)
en roken (OR 2, BI 1.0-4.0). Deze variabelen kenden wij een score toe, van
respectievelijk 2, 1 en 1. We konden de afwijking peptisch ulcuslijden
voorspellen met een oppervlakte onder de ROC curve (AUC) van 0.71.
Toevoeging van de uitslag van niet-invasieve H pylori test verbeterde de
voorspelling van peptisch ulcuslijden niet (AUC 0.75, BI 0.66-0.83). Echter, in
een subgroep met een hoog risico op het hebben van een peptisch ulcus
(gedefinieerd als patiënten met een score van 2 of meer) gaf de niet-invasieve H
pylori test relevante informatie voor het diagnosticeren van peptische ulcera,
omdat de voorafkans in deze groep (16%) steeg naar 26% na een positieve H
pylori testuitslag. Wij concludeerden, dat het testen op H pylori infectie bij alle
patiënten met maagklachten niet zinvol is. Echter, in een subgroep met een
hoog risico op het hebben van een peptisch ulcus, geeft een H pylori test
nuttige, additionele diagnostische informatie.
Hoofdstuk 4: validering van enkele niet-invasieve H pylori testen
In dit hoofdstuk werden drie niet-invasieve H pylori testen geëvalueerd om de
meest nauwkeurige en efficiënte test te identificeren in de huisartsensetting.
Een vingerpriktest, een ELISA en een 13C ureum ademtest werden gevalideerd
aan de hand van twee verschillende gouden standaarden, die gebaseerd waren
op de uitslagen van biopten bij gastroscopie verkregen. De positief
voorspellende waarde van de vingerpriktest was 71-75%, van de ELISA 83-86%
en 88-92% van de ademtest; de negatief voorspellende waarden waren
respectievelijk 72-77%, 96-100% en 95-98%. De sensitiviteit van de
vingerpriktest was 36-42%, van de ELISA  93-100% en 92-97% van de ademtest;
de specificiteit was respectievelijk 92-93%, 90-91% en 93-95%. Zowel de ELISA
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als de ademtest bleken te voldoen in de eerstelijn. Echter, bij lage H pylori
infectiegraad presteerde de ELISA slechter dan de ademtest, getuige de lagere
positief voorspellende waarde. Derhalve werd geconcludeerd dat de ademtest
de test van eerste keus is als niet-invasive H pylori test in de eerstelijn.
Hoofdstuk 5: validering van een nieuwe EIA voor H pylori infectie
Een recent ontwikkelde immunoassay voor de opsporing van H pylori infectie,
de Pyloriset® EIA-G III werd geëvalueerd in de huisartspraktijk. De
diagnostische nauwkeurigheid en het optimale afkappunt werden bepaald,
met name in een subgroep van patiënten die minder dan een jaar
maagklachten hadden. Bij 113 patiënten met maagklachten werd een ademtest,
snelle urease test, een histologische bepaling en serologie op H pylori infectie
afgenomen. Bij het optimale afkappunt van 40 eenheden per milliliter (IU/ml)
was de positief voorspellende waarde 92.1%, de negatief voorspellende waarde
96.3, de sensitiviteit 87.5% en specificiteit 93.9%. De correlatie tussen de
ademtest, de voormalige Pyloriset® EIA-G New en de Pyloriset® EIA-G III was
hoog. Bij het optimale afkappunt van 40 IU/ml bleek de nieuwe Pyloriset®
EIA-G III een betrouwbare methode om H pylori infectie in de eerstelijn op te
sporen.
Hoofdstuk 6: implementatiestudie
Gebaseerd op de resultaten van hoofdstuk drie werd een klinisch algoritme
voor de opsporing van peptische ulcera ontwikkeld en geïntroduceerd in de
huisartspraktijk. We evalueerden of huisartsen vaker werkten volgens de
richtlijn, als de introductie plaatsvond door nascholing of door een financiële
stimulus, in vergelijking met “routine” introductie waarbij de huisarts alleen
de richtlijn werd toegezonden. Zes groepen huisartsen (HAGRO’s) werden
willekeurig verdeeld over drie onderzoeksarmen: nascholing, financiële
stimulus of een controlegroep. 28 huisartsen afkomstig van 6 HAGRO’s deden
mee aan het onderzoek en includeerden 260 patiënten. De primaire
uitkomstmaat, het volgen van de richtlijn, werd geëvalueerd aan de hand van
het aantal patiënten dat volgens de richtlijn werd behandeld. De kwaliteit van
leven en dyspepsiescore van de patiënten werden als secundaire
uitkomstmaten geëvalueerd. Na correctie voor de niet ingesloten patiënten en
mogelijke verstorende variabelen, bleek dat de richtlijn het vaakst gevolgd
werd in de groep huisartsen die nascholing kregen (49%). De richtlijn werd
even goed gevolgd in de groep huisartsen die een financiële stimulus ontving
als in de controlegroep (respectievelijk 32 en 34%). De secundaire
uitkomstmaten kwaliteit van leven en dyspepsie score waren identiek in de
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drie groepen. De kosten die gemaakt werden in relatie tot de
dyspepsieklachten kwamen overeen in de drie groepen, maar waren het laagst
in de groep huisartsen die een financiële prikkel ontvingen. Ons onderzoek
toont aan dat de introductie van de richtlijn met nascholing effectiever is dan
introductie met een geringe financiële stimulus of de routine introductie.
Hoofdstuk 7: discussie en aanbevelingen
Het is niet zinvol om bij alle patiënten met maagklachten te testen op H pylori
infectie; maar bij een groep patiënten met een hoog risico op het hebben van
een peptisch ulcus (vastgesteld m.b.v. anamnese) voegt de H pylori test
belangrijke diagnostische informatie toe. Ons inziens, is de ademtest de eerste
keus test voor de opsporing van H pylori infectie in de eerstelijn. Nascholing
had een duidelijk positief effect in vergelijking tot de controlegroep op het
navolgen van de nieuw ontwikkelde richtlijn voor maagklachten. De beperkte
financiële prikkel die wij de huisartsen gaven had geen positief effect op het
volgen van de richtlijn. Omdat er aanwijzingen bestaan dat gecombineerde
strategieën voor het introduceren van een richtlijn succesvoller zijn dan
individuele strategieën, zou de combinatie van nascholing en een financiële
prikkel moeten worden onderzocht in vergelijking met de routine introductie
van een richtlijn in de eerstelijn.
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Van het gehele proefschrift heeft het dankwoord de grootste impact ……….
(extra stelling behorende bij het dankwoord)
Het is zover; de drie onderzoeksjaren zitten er (bijna) op. Het boekje is af, en
een nieuw hoofdstuk in mijn leven gaat beginnen: de opleiding tot huisarts.
Maar eerst mag ik nog terugkijken in de tijd en een aantal mensen danken voor
hun rol in de totstandkoming van dit proefschrift.
Het begon allemaal met een studentenonderzoekje op de interne
geneeskunde in het LUMC. Onder leiding van Dr. Hanno Pijl, internist,
verrichte ik onderzoek naar de epidemiologie van diabetes mellitus. Beste
Hanno: ik ben jou veel dank verschuldigd, tenslotte was jij degene, die mij liet
zien hoe leuk onderzoek doen kon zijn. Jouw enthousiasme bracht mij ertoe de
stoute schoenen aan te trekken en in Boston een onderzoeksproject te gaan
doen. Je hielp me door het schrijven van aanbevelingsbrieven en bij de
fondsenwerving. Ook na die onderzoekstijd hielden we contact en bleef je op
de hoogte van mijn bezigheden. Dat jij mijn paranimf zou worden, leek mij
vanzelfsprekend!
In Boston mocht ik aan een van de meest gerenommeerde
universiteiten ter wereld, Havard University, onderzoek doen. Op de afdeling
Epidemiology and Genetics werkte ik onder begeleiding van Dr Jim Warram
aan een grote studie over het vóórkomen van type II diabetes in families. Dear
Jim: thank you for giving me the opportunity to come to the Joslin Diabetes
Center and perform a research project at your department. My scientific career
had its basis in Boston: thank you once again!
Vanuit Leiden vetrok ik naar Utrecht om aan de afdeling
Huisartsgeneeskunde van het Julius Centrum voor Huisartsgeneeskunde en
Patiëntgebonden onderzoek een onderzoek te gaan doen naar maagklachten en
de mogelijke rol die de Helicobacter pylori bacterie daarin zou kunnen spelen.
Aanvankelijk vond het onderzoek plaats in de regio Utrecht, daarna
werd het gebied uitgebreid met de Gelderse Vallei, Leusden, Nunspeet,
Apeldoorn en de regio Deventer. Bijzondere dank ben ik verschuldigd aan alle
huisartsen en assistentes die, naast hun “gewone” verplichtingen, nog tijd
wisten vrij te maken om mee te doen met mijn onderzoeksproject. We hadden
intensief contact via telefoontjes, faxen en bezoeken, om zo het onderzoek in
goede banen te leiden en succesvol te maken. Ik hoop dat ik een goede balans
heb gehouden tussen niet teveel en niet te weinig herinneringen om aan mijn
project te blijven denken. Dank voor jullie geweldige inzet!
De patiënten die mee hebben gedaan dank ik voor hun medewerking.
In grote getale gingen zij naar het huisartsenlaboratorium, de endoscopie
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afdeling en vulden zij de vragenlijsten die bij het onderzoek hoorden in. Ik
hoop dat de resultaten uit dit onderzoek zullen leiden tot een beter beleid bij
patiënten met maagklachten in de huisartspraktijk.
De gastroenterologen uit de regio dank ik voor de gastroscopieën en
de extra biopten die er werden genomen voor mijn onderzoek: het was
bijzonder prettig om met jullie samen te werken.
De medewerkers van huisartsenlaboratoria van het Hofpoort
Ziekenhuis Woerden, het Lorentz Ziekenhuis Zeist, het Diakonessenhuis
Utrecht en de Stichting Artsenlaboratorium Utrecht dank ik voor het afnemen
en analyseren van de bloedmonsters en de ademtesten, de samenwerking liep
echt gesmeerd! Met name dank ik Mieke van der Geest, Wim Verweij, Sjannie
Klerx en Henriët Hendriks van de SAL, jullie waren een geweldig team om
mee samen te werken!
Het onderzoek werd verricht in de AEOLUS projectgroep, een zeer
inspirerend team met experts op het gebied van maagklachten, epidemiologie
en statistiek.
Promotor professor Verheij, beste Theo: jij was de baas van het
onderzoeksteam en had de, niet altijd even gemakkelijke, taak om ons
onderzoek te leiden. Dank voor je toewijding, je kritische blik op manuscripten,
het vertalen van de onderzoeksresultaten naar de dagelijkse praktijk en voor
het behouden van het overzicht van het project. Je gaf me de kans om naast het
onderzoek ook in de praktijk bezig te kunnen zijn, hetgeen erg belangrijk voor
mij was.
Promotor professor Hoes, beste Arno: als ras-epidemioloog beet je je
vast in met name het diagnostische deel van het project. Samen verkenden wij
de grenzen van ROC curves en ingewikkelde subgroep analyses (nee, dat is
geen meisjesnaam), en dat was voor ons beide een uitdaging. In korte tijd
bracht je me veel zaken bij, het vrijdag privé epidemiologie onderwijs zal ik
zeker missen. Dank voor je begeleiding van het project, ik beloof je dat ik de
epidemiologie registratie zal halen zodra ik tijd heb, ok? Maar eerst de
huisartsopleiding....
Co-promotor dr de Wit, beste Niek: gedurende de drie jaren was je
mijn vaste begeleider. Vanaf het begin liepen de zaken rond het project al
gesmeerd en vorderde het gestaag. Je rotsvaste bewaking van de voortgang
van het project was een garantie tot succes. Behalve hard werken was er
gelukkig genoeg tijd voor andere zaken en had je ook oog voor zaken buiten
“onderzoeksland”. Je wijze woorden “laat je niet gek maken” hielpen me op
die momenten dat zaken niet precies gingen zoals ik het zou willen. Als geen
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ander verdien jij alle lof voor je begeleiding, het was een plezier om met je te
mogen samenwerken!
Co-promotor dr Numans, beste Mattijs: Het AEOLUS project is naast
mijn project met name het kindje van Niek en van jou. Voor de regio zijn jullie
voorgoed verbonden aan “maagklachten” en daar heb ik graag gebruik van
gemaakt. Dank voor je enthousiasme voor het onderwerp, de tijd om “jouw”
model uit te breiden en als een juweeltje te mogen publiceren. Ook gaf je me de
gelegenheid om meteen al betrokken te zijn bij de regionale nascholingen op
het gebied van maagklachten, dat was een unieke kans om veel collegae uit het
veld te leren kennen. Ik ben ervan overtuigd dat we elkaar in de toekomst nog
veel zullen spreken!
Professor Smout, beste André. Jij speelde een dubbelrol in mijn
onderzoekstijd. Als gastroenteroloog was jij verbonden aan het AEOLUS
project en adviseerde je vanuit het perspectief van de specialist (gelukkig met
een huisartsgeneeskundige bril op). Ik kreeg ook de unieke kans om gedurende
twee jaren met je in de kliniek samen te mogen werken, je bent een fantastische
leermeester!
Professor Kuipers, beste Ernst: als externe adviseur van het AEOLUS
project maakte je je rol meer dan waar. Via met name de email hadden we
intensief contact over onderzoeksresultaten en geschreven artikelen. Ik ben
zéér onder de indruk van jouw planning en toewijding voor onderzoek. Dank
voor al je nuttige adviezen en commentaar.
Renate Siebes: je was “mijn” eerste onderzoeksassistente. Dank voor je
inzet voor het AEOLUS project. De praktijkbezoeken (inclusief kerstkransen op
de achterbank) zal ik nooit meer vergeten! Veel succes met je eigen
promotieonderzoek.
Frances Verheij: als onderzoeksassistente was je ruim twee jaar mijn
trouwe steun. Vlekkeloos hield jij bij wie er gemaild moest worden, maakte
afspraken voor bezoeken aan praktijken en zorgde je voor alle andere
logistieke zaken. Toen ik je om hulp vroeg voor het lay-out werk twijfelde je
geen moment. Jij verdient echt alle lof en een grote pluim. Ik hoop dat nog vele
onderzoekers met jou mogen samenwerken!
Peter Zuithoff: als “statistiek analfabeet” arriveerde ik in Utrecht. In
korte tijd leerde je mij de kneepjes van SPSS kennen. Samen worstelden we ons
door ROC curves, subgroepanalyses en tot slot ook nog de mulitlevel-wereld.
Bewondering heb ik voor je geduld en trouw, met name als zaken toch weer
net iets anders geanalyseerd moesten worden. Mede dankzij jouw hulp werd
het project in drie jaar succesvol afgerond, heel veel dank daarvoor.
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“Young HAG” Ineke Welschen, Sandra van Loon, Marianne van Zwet,
Barbara Tanis, Frans Rutten, Lex Goudswaard, Ruud Oudega, Cees van Beek,
Wim Opstelten, Birgit van Staaij en (o.s.m) Bert-Jan de Boer: als promovendi
deelden we lief en leed van het onderzoek doen en vele zaken daarbuiten. Het
gaf mij het gevoel er niet alleen voor te staan. Dank voor de gezellige lunches,
koffiepauzes en andere gezamenlijke activiteiten. Jullie interesse en steun, met
name in de eindfase, was heel plezierig! Ik wens jullie veel succes bij de
afronding van jullie projecten, hou me op de hoogte!
Kamergenoot dr Hak, beste Eelko. Geruime tijd deelden wij het
onderzoekspaleisje 6.139 van HAG. Ook al gingen onze vele gesprekken niet
altijd over ons werk, we presteerden het beiden om onze projecten op tijd
succesvol af te ronden. Jouw kennis van de epidemiologie was voor mij vaak
een nuttige steun. Dank dat je mijn geklets hebt willen aanhoren. Ik wens je
heel veel succes voor je verdere loopbaan, en wie weet, kan ik als huisarts nog
eens meedoen aan een van jouw onderzoeken!
Dr Nicoline Lewin: dank voor je hulp toen ik in Utrecht met mijn
onderzoeksproject begon. Je gaf nuttige adviezen om een goede start te kunnen
hebben. Dank ook voor de SCOoPE data die ik kon gebruiken om mijn
“model” mee te bouwen. We komen elkaar beslist in Huisartsenland weer
tegen!
Dr Otto Quartero: als mede BUIK onderzoeker was je uitstekend op de
hoogte van de ontwikkelingen rond mijn onderzoeksproject. Je gaf nuttige
adviezen over de inhoud van AEOLUS, becommentarieerde artikelen en hielp
bij het werven van huisartsen voor de tweede fase van het project. Ook mocht
ik data van jouw CIRANO project gebruiken voor mijn vragenlijsten en model.
Ik hoop in de toekomst bij het "BUIKclubje" betrokken te blijven en wens je
veel succes met de geplande onderzoeken.
Alle collegae van HAG dank ik voor de plezierige sfeer en fijne
samenwerking op de afdeling. Ineke v.d. Hoeven: dank voor alle hulp bij het
regelen van “van-alles-en-nog-wat”, een aanspreekpunt zoals jij is echt goud
waard.
Collegae van de GIM-poli: ruim twee jaar trok ik op de dinsdag de
witte jas aan (en kreeg daardoor veel commentaar van de huisartsen op de
afdeling) om op de motiliteitspoli van het AZU te gaan werken. In een uniek,
hecht team bestaande uit chirurgen, gastroenterologen, psycholoog en diëtiste
kreeg ik de kans om meer te leren over de maag en de darmen. De vaak
meespelende psychische factoren waren voor mij een goede leerschool, en zijn
nu goede bagage voor mij als toekomstig huisarts. Dank voor de leermomenten
en natuurlijk de humor waarmee jullie het werk op de poli deden. Ik hoop dat
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jullie mijn inbreng vanuit de huisartsgeneeskunde hebben kunnen waarderen
(hebben we de huisarts al gebeld over deze patiënt?), ik zal jullie missen!
Papa en mama: dank voor al jullie steun in de afgelopen jaren.
Ondanks dat ik al vroeg het huis verliet waren jullie altijd uitstekend op de
hoogte van mijn doen-en-laten. Dank dat jullie me hebben gevolgd, waar mijn
omzwervingen mij ook brachten. Jullie voortdurende interesse gaf mij veel
energie om extra mijn best te doen, jullie zijn geweldig!
Mijn zus Micha: wij hebben een bijzondere band, en daar ben ik heel
blij mee. De geneeskunde leerde jij al heel vroeg van een andere kant kennen,
bewondering heb ik voor je vechtlust en doorzettingsvermogen. Dank dat je
me stimuleerde met waar ik mee bezig was, dat heeft me héél vaak geholpen.
Vrienden en familie dank ik voor de belangstelling voor mijn werk.
Miriam Blaauboer, mijn tweede paranimf: jij neemt een heel bijzondere plek in
mijn hart in. Wales, Leiden, Boston, promotieonderzoek en nog veel meer, wij
delen heel veel zaken. Ook al waren we de afgelopen jaren niet heel dichtbij
elkaar, de email en telefoon zorgde ervoor dat we goed op de hoogte bleven
van ontwikkelingen. Ik hoop dat je voorlopig in Nederland blijft en dat onze
vriendschap nog sterker zal worden!
Tot slot natuurlijk mijn partner Robert Enters. Lieve Robert: ik ben je
héél véél dank verschuldigd. Van dichtbij maakte jij de pieken en de dalen van
dit onderzoeksproject mee. Jij straalde de rust uit die nodig was om het werk
succesvol af te kunnen ronden. Twee drukke banen zijn niet altijd even
makkelijk te combineren, maar wij zijn een uitstekend team! Je steun was (en
is) onmisbaar. Ik verheug me op onze verdere toekomst samen en de vele
avonturen in binnen- en buitenland die ons nog te wachten staan.
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